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SOMMARIO 
L’Atrofia Multisistemica (MSA) è una malattia neurodegenerativa grave con 
un’incidenza di 0,6 casi per 100000 persone/anno, ad insorgenza in età 
adulta e con una sopravvivenza di 6-9 anni dalla diagnosi. Clinicamente, la 
MSA è caratterizzata da parkinsonismo, atassia cerebellare, disautonomia e 
segni piramidali. In base alla prevalenza dei sintomi parkinsoniani o 
cerebellari si identificano due sottotipi di malattia, rispettivamente MSA-P e 
MSA-C.  Dal punto di vista neuropatologico, la MSA rientra nell’ambito delle 
alfa-sinucleinopatie. Tuttavia, a differenza della malattia di Parkinson e della 
demenza a corpi di Lewy, nell’MSA l’alfa-sinucleina non si accumula tanto a 
livello neuronale quanto a livello oligodendrogliale.  
Al momento non esistono terapie efficaci. 
La patogenesi della malattia è quasi del tutto sconosciuta e i modelli 
attualmente disponibili, prevalentemente animali transgenici ottenuti 
overesprimendo alfa-sinucleina umana sotto il controllo di promotori di geni 
specificamente espressi a livello oligodendrogliale, non ne ricapitolano 
pienamente i meccanismi patogenetici. 
Lo scopo di questo progetto è stato la generazione e lo studio di nuovi modelli 
sperimentali mirati alla valutazione dei meccanismi patogenetici della 
malattia e all’identificazione di nuovi obiettivi terapeutici. 
Lo studio si è basato sull’utilizzo di cellule di sangue periferico, colture 
primarie di fibroblasti, neuroni dopaminergici derivati da cellule staminali 
pluripotenti indotte (iPSCs) e tessuto cerebrale. Le tematiche esaminate 
sono state molteplici, comprendendo l’autofagia, la funzionalità 
mitocondriale e l’espressione di alfa sinucleina. 
Le principali alterazioni riscontrate nei pazienti sono state: un aumento della 
quantità di DNA mitocondriale nelle cellule di sangue periferico e nel tessuto 
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cerebrale, selettivamente nella forma cerebellare di malattia; una 
compromissione dell’attività della catena respiratoria mitocondriale nei 
fibroblasti e nei neuroni; un incremento della massa mitocondriale e della 
quantità di complesso II, un incremento dell’espressione di geni mitocondrio-
correlati, un incremento della quantità di numerosi enzimi coinvolti nella 
sintesi del Coenzima Q10 nei neuroni; un’alterazione dell’autofagia nei 
neuroni; una ridotta espressione di marcatori neuronali nelle fasi avanzate 
del differenziamento dopaminergico; l’ipometilazione di una CpG island 
collocata nell’introne 1 del gene dell’alfa-sinucleina. 
E’ di particolare rilievo la generazione e la caratterizzazione del modello 
neuronale derivato da iPSCs, in quanto rappresenta il primo modello 
completo di MSA basato su questa tecnica. 
Nel complesso, questo progetto ha portato all’identificazione di numerosi 
difetti nelle cellule e nei tessuti di pazienti affetti da MSA che suggeriscono 
una disfunzione di specifici processi molecolari e contribuiscono alla 
comprensione dei sottostanti meccanismi patogenetici. Inoltre, questo studio 
pone le basi per numerose linee di ricerca e il modello qui descritto può 
presentare notevoli applicazioni in campo terapeutico, grazie all’opportunità 
di valutare l’efficacia e la tollerabilità di nuovi composti farmacologici.  
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ABSTRACT 
Multiple System Atrophy (MSA) is a severe adult-onset neurodegenerative 
disease, with an incidence of 0.6 per 100000 persons/year and a survival 
rate of 6-9 years from the onset. MSA is clinically characterized by 
parkinsonism, cerebellar ataxia, dysautonomia and pyramidal signs. Two 
subtypes of the disease can be distinguished, MSA-P and MSA-C, on the 
basis of the predominant symptomatology, parkinsonian or cerebellar 
respectively. From a neuropathological point of view, MSA is classified as an 
alpha-synucleinopathy. However, differently from Parkinson’s disease and 
Dementia with Lewy bodies, the main intracellular localization of alpha-
synuclein aggregates in MSA is not the neuron, but the oligodendrocyte.  
An effective therapy is not available yet. 
The pathogenesis of the disease is almost completely unknown and the 
available models, mainly transgenic animals overexpressing human alpha-
synuclein under the promoter of genes specifically expressed in 
oligodendrocytes, do not fully recapitulate the pathogenic mechanisms. 
The aim of the present project was the generation and study of new 
experimental models for the identification of the molecular mechanisms of 
the disease and new therapeutic targets. 
The study has taken advantage from the use of peripheral blood cells, 
fibroblasts’ primary cultures, iPSC-derived dopaminergic neurons and brain 
tissue and has focused on several topics, including autophagy, mitochondrial 
functioning and alpha-synuclein expression. 
The main findings in patients have been: an increase of mtDNA amount in 
peripheral blood cells and in brain tissue, selectively in the cerebellar 
subtype; an impairment of mitochondrial respiratory chain activity in 
fibroblasts and iPSC-derived neurons; an increase of mitochondrial mass 
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and of complex II amount, an increased expression of mitochondria-related 
genes, an increase of the amount of many enzymes involved in the synthesis 
of Coenzyme Q10 in neurons; an impairment of the autophagic pathway in 
neurons; a reduced expression of neuronal markers in advanced stages of 
dopaminergic differentiation; hypomethylation of a CpG island located in 
alpha-synuclein intron 1. 
The generation and characterization of the iPSC-derived neuronal model is 
particularly remarkable because it represents the first comprehensive model 
of MSA based on this technique. 
In conclusion, this project has led to the identification of several defects in 
MSA cells and tissues, suggesting the impairment of specific molecular 
pathways and contributing to the understanding of the underlying pathogenic 
mechanisms. Furthermore, this study lays the foundations for several lines 
of investigation and the proposed model can also have remarkable 
therapeutic implications for the assessment of effectiveness and tolerability 
of new pharmacological compounds. 
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INTRODUCTION 
Multiple System Atrophy (MSA) is a progressive adult-onset 
neurodegenerative disorder which affects several areas of the nervous 
system. The clinical presentation is heterogenous and is characterized by 
parkinsonian, cerebellar, autonomic and pyramidal features. An effective 
therapy is not available yet. Alpha-synuclein accumulation, mainly in 
oligodendroglia, is the main neuropathological finding, but almost nothing is 
known about the pathogenic mechanisms. The purpose of the present thesis 
project is the development and study of innovative models which may help 
to dissect the pathological mechanisms of this invalidating disorder and lay 
the basis for the future development of new drugs. 
 
Clinical presentation and diagnosis 
Multiple System Atrophy (MSA) is a severe and progressive 
neurodegenerative disease, which is clinically characterized by 
parkinsonism, cerebellar ataxia, dysautonomia and pyramidal signs in 
different combinations. (Fanciulli and Wenning, 2015; Krismer and Wenning, 
2017) 
Estimated incidence is 0.6 per 100000 person-years, but a considerable 
variability has been observed in different geographical areas. Being MSA a 
late-onset disease, incidence is highly age-dependent and reaches the value 
of 3 per 100000 person-years over 50 years of age.  
Onset is usually in the sixth decade of life and mean survival is 6-9 years. 
The denomination “Multiple System Atrophy” is of recent use and it denotes 
a spectrum of disorders which were previously denominated striatonigral 
degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome.  
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Two diffferent subtypes of the disease can be distinguished (MSA-P and 
MSA-C) on the basis of the predominant symptomatology at onset, 
parkinsonian or cerebellar respectively. 
MSA-P is the widely most common form in Western countries, representing 
80 % of cases, whereas MSA-C is the most diffuse presentation in the 
Japanese population. 
Parkinsonism usually manifests with a rapidly progressive akinetic-rigid 
symptomatology comprehending muscle stiffness, resistance to passive 
movements and slow movements. 
Cerebellar symptomatology is characterized by gait and limb ataxia, 
scanning dysarthria and oculomotor symptoms. 
Dysautonomia is always found in MSA patients and includes a wide spectrum 
of signs and symptoms. Urogenital dysfunction is characterized by urinary 
incontinence, urinary frequency and urgency, incomplete bladder emptying 
and erectile dysfunction. Neurogenic orthostatic hypotension is another 
common invalidant autonomic symptom. Recurrent syncopes, weakness, 
headache, dizziness and nausea are common findings. Hypohydrosis and 
anhydrosis can also occur. 
Generalized hyperreflexia and abnormal plantar reflex are the main 
pyramidal signs that can be detected in MSA. MSA-C is more often interested 
by the pyramidal involvement. 
Many other clinical features can occur during the progression of disease, 
including axial deformities, dysphagia, sialorrhea, respiratory stridor and 
REM sleep behaviour disorder.  
The heterogeneity of clinical presentation makes the diagnostic procedure 
difficult and differential diagnosis with other diseases is often required, in 
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particular with DLB, PD, PSP and sporadic adult onset ataxia. Other 
disorders that are less commonly involved in differential diagnosis are toxin-
induced ataxias, vitamin B1 deficiency-related ataxias, immune-mediated 
ataxias, genetic ataxias (e.g. SCA6 and Friedreich ataxia). Only 62 % of 
clinically-diagnosed MSA patients have diagnosis confirmed at autopsy. 
“Definite” diagnosis can be performed only post-mortem, whereas clinical 
diagnosis can only be defined as “probable” or “possible”.   
The diagnostic criteria for definite, probable and possible MSA have been 
published by Gilman et al. in 2008 and are the following (quoted from the 
guidelines): 
- “Definite MSA”. Neuropathological finding of widespread and 
abundant central nervous system alpha-synuclein-positive glial 
cytoplasmic inclusions (Papp Lantos inclusions) in association with 
neurodegenerative changes in striatonigral and olivopontocerebellar 
structures. 
- “Probable MSA”. A sporadic, progressive, adult onset disease 
characterized by: autonomic failure involving urinary incontinence 
(inability to control the release of urine from the bladder, with erectile 
dysfunction in males) or an orthostatic decrease of blood pressure 
within 3 minutes of standing by at least 30 mmHg systolic or 15 mmHg 
diastolic AND poorly levodopa-responsive parkinsonism 
(bradykinesia with rigidity, tremor or postural instability) OR a 
cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb 
ataxia or cerebellar oculomotor dysfunction). 
- “Possible MSA”. A sporadic, progressive, adult onset disease 
chracterized by: parkinsonism (bradykinesia with rigidity, tremor or 
postural instability) OR a cerebellar syndrome (gait ataxia with 
cerebellar dysarthria, limb ataxia or cerebellar oculomotor 
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dysfunction) AND at least one feature suggesting autonomic 
dysfunction (otherwise unexplained urinary urgency, frequency or 
incomplete bladder emptying, erectile dysfunction in males or 
significant orthostatic blood pressure decline that does not meet the 
level required in probable MSA) AND at least one of the listed 
additional features (Babinski sign with hyperreflexia, stridor, rapidly 
progressive parkinsonism, poor response to levodopa, postural 
instability within 3 years of motor onset, gait ataxia, cerebellar 
dysarthria, limb ataxia or cerebellar oculomotor dysfunction, 
dysphagia within 5 years of motor onset, atrophy on MRI of putamen, 
middle cerebellar peduncle, pons or cerebellum, hypometabolism on 
FDG-PET in putamen, brainstem or cerebellum, parkinsonism, 
atrophy on MRI of putamen, middle cerebellar peduncle or pons, 
hypometabolism on FDG-PET in putamen, presynaptic nigrostriatal 
dopaminergic denervation on SPECT or PET). 
Furthermore, many tools can be of help in the diagnostic procedure. 
Atrophy of putamen, pons and middle cerebellar peduncle and dilation of the 
fourth ventricle can be observed at MRI images. Furthermore, two MRI signs 
at T2 weighted images are indicative of MSA: the “putaminal slit” 
(hyperintensity of putaminal margin) and the “hot cross bun” (pontine 
cruciform hyperintensity). 
18F-FDG-PET images display a reduced striatal glucose metabolism, 
whereas SPECT shows areas of reduced perfusion in striatum, brainstem 
and cerebellum in MSA patients. (Tang et al., 2010; Poston et al., 2012; 
Poston and Eidelberg, 2012) 
The evaluation of D2 receptor ligands aimed to assess post-synaptic 
dopaminergic function can be useful for differential diagnosis with PD 
(Brooks and Seppi, 2009), whereas the degeneration of pre-synaptic 
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striatonigral terminals in both PD and MSA reduces the usefulness of the 
assessment of presynaptic dopaminergic function with 18F-fluorodopa-PET 
or 123I-β-CIT-SPECT. 
 
 
Therapeutic approaches 
An effective therapy is not available yet, but some symptomatic treatments 
are currently in use. (Krismer and Wenning, 2017) 
Parkinsonian symptoms are usually treated with dopamine agents and 
levodopa is the agent of choice, since 40 % of MSA patients have shown a 
beneficial response to the administration of this compound. Dopamine 
agonists, such as ropinirole, pramipexole, lisuride, cabergoline or rotigotine 
have shown lower tolerability and poorer efficacy in patients. 
Amantadine effect has been assessed in two trials, without positive results. 
Local dystonia can be treated with botulin toxin injections  
Botulin toxin injections and anticholinergic drugs can be used to treat 
sialorrhea, despite the adverse effects of anticholinergic compounds 
(confusion, impaired concentration, drowsiness, memory impairment and 
attention defict). 
Anticholinergic drugs can also be used for the treatment of urogenital 
symptoms, in particular for detrusor hyperreflexia and detrusor-sphyncter 
dyssynergia.  
Regular clean intermittent catheterization can be necessary in case of 
increased post-mictutrition volumes whereas urethral obstructions can 
require transcutaneous suprapubic catheterization. 
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Erectile dysfunction can benefit from cGMP specific phosphodiesterase type 
5 inhibitors (e.g. sildenafil), although orthostatic hypotension is exacerbated 
by such compounds. 
Constipation should be treated with non-pharmacological measures (high 
fluid and fibre intake and exercise) and with the administration of laxatives 
(e.g. calcium polycarbophil and mosepride citrate). 
Also cardiovascular autonomic dysfunction requires several therapeutic 
interventions, both non-pharmacological and pharmacological. Physical 
counter-manoeuvres should be used for orthostatic hypotension, such as 
stockings and abdominal binders. Large meals should be discouraged and 
sufficient fluid intake and high-salt diet are warranted. Moreover, night-time 
head-up tilt reduces supine hypertension, nicturia and orthostatic 
hypotension in the morning. The α1-receptor agonist compound midodrine 
alleviates hypotension, as well as the noradrenaline precursor droxidopa, the 
corticosteroid fludrocortisone and the acetylcholinesterase inhibitor 
pyridostigmine. Blood pressure elevating drugs should be avoided in late 
afternoon or evening to avoid night-time hypertension. Nicturia can be 
alleviated by the administration of the antidiuretic compound desmopressin. 
Several pharmacological trials have been completed or are ongoing for the 
treatment of MSA.  
In particular, 7 interventional trials have already been completed and have 
assessed the effect of mesenchymal stem cell autologous transplantation 
(Lee et al., 2012), riluzole (Bensimon et al., 2009), minocycline (Dodel et al., 
2010), growth hormone (Holmberg et al., 2007), rifampicin (Low et al., 2014), 
lithium (Sacca et al., 2013) and rasagiline (Poewe etal., 2015) in MSA 
patients. However, none of these trials have provided positive results, with 
the exception of the one assessing the effect of mesenchymal stem cell 
transplantation. In that case, autologous mesenchymal stem cells were 
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delivered intra-arterially at day 0 and intra-venously at days 30, 60 and 90. A 
p value of 0.047 was obtained, assessing changes in the Unified Multiple 
System Atrophy Rating Scale (UMSARS) as primary outcome. However, the 
UMSARS improvement was also accompanied by the finding of multiple 
small cerebral infarcts at MRI, in one case clinically symptomatic. 
The ongoing interventional trials are related to the assessment of the 
myeloperoxidase inhibitor AZD3241 (phase II), autologous mesenchymal 
stem cell transplantation (phase I), epigallocatechin gallate (phase II) and 
alpha-synuclein immunization (phase I). 
However many therapeutic strategies are being studied, mainly related to 
alpha-synuclein pathology. In particular, alpha-synuclein-related therapeutic 
strategies may target alpha-synuclein expression, alpha-synuclein 
aggregation, alpha-synuclein degradation and clearance and alpha-
synuclein cell-to-cell propagation (Valera et al., 2016). 
The effect of antisense small interfering RNA (siRNA) or short hairpin RNA 
(shRNA) has already been tested on animal and in vitro models of PD 
overexpressing SNCA gene with encouraging results, but not in MSA.  
(Takahashi et al., 2015; Zharikov et al., 2015) 
Alpha-synuclein aggregation could be targeted through specific agents, such 
as the inhibitor Anle 138b, already studied in animal models of PD, or the 
iron chelation agent epigallocatechin gallate whose effect in MSA is being 
assessed in a clinical trial. (Wagner et al., 2013; Lorenzen et al., 2014) 
Apha-synuclein degradation and clearance can be targeted through various 
stratategies, such as the stimulation of autophagy, the modulation of 
phagocytic activty of microglia and the administration of extracellular 
degrading enzymes.  
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Furthermore alpha-synuclein accumulation has been found to be reduced by 
antiinflammatory agents, in particular some antidepressants (Valera et al., 
2014; Ubhi et al., 2012) and immunomodulatory compounds (Valera et al., 
2015), in animal models of synucleinopathies. Also the immunomodulatory 
and anticancer drug lenalidomide has been tested on the MBP-tg-mouse-
model of MSA, showing a reduction of alpha-synuclein positive cells in 
striatum and a normalization of proinflammatory microglial phenotype 
(Valera et al., 2016). Furthermore, as myeloperxidase inhibition has been 
found to be associated with an improvement of both clinical and pathological 
features of the 3NP model of MSA (Stefanova et al., 2012) a phase II clinical 
trial is currently ongoing in MSA patients with the compound AZD3241.  
The last pharmacological mechanisms which are under consideration for 
MSA are related to alpha-synuclein cell-to-cell propagation: extracellular 
alpha-synuclein degrading enzymes (e.g. matrix metalloproteinases, plasmin 
or neurosin, which has shown to reduce alpha-synuclein in oligodendrocytes 
and alpha-synuclein spread to glial cells in a mouse model of MSA) (Tatebe 
et al., 2010; Spencer et al., 2013; Spencer et al., 2015; Park et al., 2013) and 
immunization against alpha-synuclein, both passive and active. The tool of 
immunization is particularly promising, having been widely assessed in pre-
clinical models and being now tested in clinical trials. (Masliah et al., 2011; 
Valera et al., 2013; Mandler et al., 2014; Mandler et al., 2015) Passive 
immunization is already undergoing a phase I trial aiming to assess the effect 
of anti-alpha-synuclein antibodies PRX002 and BIIB054 in patients. Also 
active immunization is being investigated through the administration of small 
peptides which mimic alpha-synuclein C-terminus. 
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Neuropathology 
The complexity of MSA clinical phenotype finds a pathological correlate in 
the large number of areas of the nervous system which are affected. 
From the macroscopic point of view, putaminal atrophy, brainstem nuclei 
pale pigmentation and cerebellar and pontine atrophy are the main 
neuropathological findings. (Jellinger, 2014) 
Microscopically, glial cytoplasmic inclusions (GCIs) are the most important 
hallmark of the disease. GCIs are argyrophilic intracellular aggregates, 
mainly composed of alpha-synuclein, which are located in oligodendrocytes. 
(Jellinger, 2014; Jellinger and Lantos, 2010; Papp et al., 1989; Papp and 
Lantos, 1992; Papp and Lantos, 1994; Lantos and Papp, 1994) The 
presence of alpha-synuclein aggregates in patients is the rationale for the 
inclusion of MSA, together with Parkinson’s disease (PD) and Dementia with 
Lewy bodies (DLB), in the group of alpha-synucleinopathies. However, the 
selectivity of these aggregates for oligodendroglia differentiates MSA from 
PD and DLB, where alpha-synuclein aggregates are mainly found in 
neurons. Although GCIs are widely distributed in the nervous system, a 
region-specific selectivity can be observed. Pons, medulla, putamen, 
substantia nigra pars compacta, cerebellum and preganglionic autonomic 
structures are the most affected areas. Furthermore, even inside these 
specific regions of the nervous system, a further selectivity of GCIs for 
specific cellular subpopulations can be observed. For example, in the 
putamen only calcineurin-positive medium spiny neurons degenerate, 
whereas ChAT-positive neurons are relatively spared. (Sato et al., 2007)  
As already stated, alpha-synuclein is the main constituent of GCIs. However, 
alpha-synuclein is not usually found in its basal form, but often undergoes 
modifications. The phosphorylation of serine 129 residue is a common 
finding, as well as protein nitration. Furthermore, not only the monomeric 
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form of the protein, but also granular and filamentous structures are found in 
aggregates. 
In addition to alpha-synuclein, many other proteins can be detected in GCIs. 
p25alpha/TPPP (involved in myelination and supposed to trigger alpha-
synuclein aggregation), ubiquitin, microtubule-associated tau protein, prion 
disease-linked 14-3-3 protein, heat shock proteins Hsc70 and Hsp70, alpha 
and beta tubulin, microtubule associated proteins, cdk5, DARRP-32, 
HtrA2/Omi, metallothionein-III, LRRK2 and Parkin are some examples. 
Although glial protein inclusions are the main hallmark of the disease, alpha-
synuclein aggregates can be observed also in neurons, both in cytoplasm 
(neuronal cytoplasmic inclusions or NCIs) and in nuclei (neuronal nuclear 
inclusions or NNIs). NCIs and NNIs can usually be found in pontine nuclei, 
inferior olives, putamen, substantia nigra, locus coeruleus, cortical pyramidal 
neurons, lower motor neurons and intermediolateral column of thoracic 
spinal cord. Pontine basis and inferior olives are the most affected regions. 
Astrogliosis and microglial activation are other important neuropathological 
findings of MSA. 
Concerning the localization of neuropathological lesions, some differences 
exist between MSA-P and MSA-C. In MSA-P the most affected areas are 
dorsolateral caudal putamen, caudate nucleus, globus pallidus and 
subthalamic nucleus, whereas thalamic nuclei are spared. 
In MSA-C neuronal degeneration can be observed in pontine basis, 
cerebellopontine fibers, cerebellar vermis, cerebellar hemispheres, dentate 
nucleus. Striatum, substantia nigra and locus coeruleus are affected too, 
although not as heavily as in MSA-P. Pontine gray, paracerebellar nuclei and 
inferior olivary complex can display neuronal inclusions. Cerebellar 
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Purkinje’s cells, although found to degenerate, do not contain GCIs, but 
accumulate glial cell line derived neurotrophic factor (GDNF). 
Intermediolateral column of spinal cord, dorsal nucleus of vagus and 
Onufrowicz nucleus are affected both in MSA-P and in MSA-C. 
 
 
Available models 
The development of reliable models of MSA is particuarly challenging 
because of the complexity of the clinical and pathological features. (Ubhi et 
al., 2011; Fernagut et al., 2012; Stefanova et al., 2015) 
The first models were obtained through the administration of toxins to 
animals. As the main pathological features of MSA are characterized by the 
involvement of striatum and substantia nigra, it was initially proposed to 
administer toxins able to damage these specific areas. The first attempt was 
based on the injection of 6-hydroxydopamine (6-ODA) in medial forebrain 
and quinolinic acid (QA) in striatum. Although this approach effectively led to 
striatal and dopaminergic loss, it proved to be too destructive, impeding a 
correct evaluation of pathogenic mechanisms. (Ghorayeb et al., 2001) 
An alternative toxin-mediated approach was based on the intraperitoneal 
injection of 3-nitroproprionic acid (3NP) in mice. Motor dysfunction and a 
variable degree of striatal and dopaminergic degeneration was observed. 
(Fernagut et al., 2002) 
Also the effect of the concomitant administration of 3NP and MPTP was 
assessed. This approach was used also in mokeys, leading to a clinical and 
pathological phenotype which included an impaired motor behavior and the 
degeneration of putamen and caudate nucleus. However, the remarkable 
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methodological limitations strongly affected the actual application of this 
method. (Stefanova et al., 2003; Ghorayeb et al., 2000) 
The following step in modeling MSA was represented by the generation of 
transgenic animals. As the main pathological feature of the disease is the 
finding of alpha-synuclein aggregates in oligodendrocytes, the main efforts 
were devoted to recapitulate this specific phenotype. Therefore, the majority 
of transgenic animal models are represented by mice overexpressing human 
alpha-synuclein under the promoter of genes specifically expressed in 
oligodendrocytes (Ubhi et al., 2011). 
The PLP-tg-mouse-model has been generated overexpressing human 
alpha-synuclein under the promoter of proteolipid protein (PLP). These mice 
display a selective localization of the protein in oligodendrocytes and the 
pattern of protein aggregates resembles that of GCIs. The typical 
pathological feature of alpha-synuclein hyperphosphorylation at S129 can be 
observed too. (Kahle et al., 2002) Furthermore, in addition to classicaly 
affected brain regions, also other areas of the nervous system are involved. 
In particular, the degeneration of Onuf’s nucleus, peduncolopontine 
tegmental nucleus, laterodorsal tegmental nucleus, cholinergic neurons of 
nucleus ambiguus and other areas which are connected to autonomic failure 
and other non motor symptoms has been described. (Sternberger et al., 
2010) The administration of 3-nitroproprionic acid to PLP-hasyn-tg-mice 
leads to a worsening of both clinical and pathological features. In particular, 
an exasperation of motor symptoms, striatonigral and cerebellar 
degeneration, microglial activation and astrogliosis has been observed. 
(Stefanova et al., 2005) Furthermore, PLP-mice have also been used to 
assess the effect of the MAO-B inhibitor rasagiline. This compound has been 
administered to animals which had previously been treated with 3-NP acid. 
An improvement in motor behhavior and in the degeneration of substantia 
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nigra, striatum, cerebellum, pons and inferior olives has been observed. 
(Stefanova et al., 2008)  
Another transgenic mouse model has been generated overexpressing 
human alpha-synuclein under the promoter of myelin basic protein (MBP). 
These mice display a strong pathological phenotype. Human alpha-synuclein 
can be detected in oligodendrocytes of brainstem, cerebellum, basal ganglia, 
neocortex and corpus callosum. S129-phosphorylated alpha-synuclein and 
ubiquitin can be found in intracellular inclusions as well. Astrogliosis, myelin 
pallor and degeneration of dopaminergic fibers in basal ganglia are other 
feaures of these animals. (Shults et al., 2005) The effect of 3-NP acid has 
been assessed also in this model, showing a worsening of 
neurodegeneration and clinical phenotype. Moreover, an alteration of the 
levels of nitrated and oxidized alpha-synuclein (but not of the total and 
phosphorylated forms of the protein) has been detected. (Ubhi et al., 2009) 
The levels of brain-derived neurotrophic factor (BDNF), insulin like growth 
factor 1 (IGF1) and glial cell line derived neurotrophic factor (GDNF) have 
proven to be reduced in MBP-mice and the intracerebroventricular infusion 
of GDNF has been associated with an improvement of both clinical and 
pathological features. (Ubhi et al., 2010) 
A third transgenic model has been generated overexpressing human alpha-
synuclein under the promoter of 2’-3’cyclic-nucleotide-3’-phosphodiesterase 
(CNP). A motor involvement and a neurodegenerative pattern has been 
observed in these animals. (Yazawa et al., 2005) 
Finally, an atypical model has been generated overexpressing the alpha-1B 
adrenergic receptor in mice. A parkinsonian syndrome with autonomic 
dysfunction associated with the finding of alpha-synuclein aggregates in 
oligodendrocytes has been observed, although the precise mechanism at the 
basis of this phenotype is unclear. (Zuscic et al., 2000) 
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So far, very few studies have been performed to generate in vitro models of 
MSA. 
The forced expression of alpha-synuclein (both wild-type and C-terminal  
truncated forms) in glial  cell coltures has been associated with a reduction 
of cell survival and an increased vulnerability to external stress. (Stefanova 
et al., 2005) 
A recent study has described the generation of iPSC-derived 
oligodendrocytes from 1 MSA-P and 1 MSA-C patients. A reduction of alpha-
synuclein expressing cells has been observed during differentition, but a 
pathological phenotype has not been detected in these cells. (Djelloul et al., 
2015) 
 
 
Pathogenesis 
Genetics 
Differently from Parkinson’s disease, where a remarkable percentage of 
cases are due to genetic mutations (dominant or recessive, with various 
degrees of penetrance) (Bonifati, 2014), MSA is generally considered as a 
sporadic disease. However, familial aggregations have been reported 
showing autosomal dominant and autosomal recessive inheritance. (Multiple 
System Atrophy Research Collaboration, 2013; Wullner et al., 2004; Hara et 
al., 2007)  
Several studies have been carried out to explore the role of genetics in MSA. 
A possible role has been postulated for mutations in COQ2, a gene encoding 
an enzyne involved in the syntjesis of CoenzymeQ10 (Multiple System 
Atrophy Research Collaboration, 2013). Whole genome sequencing of a 
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japanese patient affected with autopsy-confirmed familial MSA displayed a 
functionally relevant mutation in COQ2. Furthermore, one common COQ2 
variant and various rare COQ2 variants have been associated with increased 
MSA risk in Japan. However, these results have not been confirmed by other 
independent studies. (Sharma et al., 2014; Schottlaender et al., 2014, Ronchi 
et al., 2016)   
An increased risk of MSA has been associated with variants in SNCA gene. 
(Scholz et al., 2009; Al-Chalabi et al., 2009) However this result was not 
confirmed by a genome wide association study (GWAS) involving 918 MSA 
patients and 3864 controls (Sailer et al., 2016). 
Environmental factors 
The role of environmental factors in the onset of the disease has been 
assessed by several studies. 
MSA has been associated with occupational exposure to organic solvents, 
plastic monomers and additives, pesticides and metals. (Nee et al., 1991) 
A European study involving 73 MSA patients, 146 hospital controls and 73 
population controls has showed an increased incidence of MSA in agriculture 
workers. (Vanacore et al., 2005). However, this observation has not been 
replicated by other studies (Cho et al., 2008; Seo et al., 2010; Vidal et al., 
2008). 
Smoking has been associated with a reduced incidence of the disease. 
(Vanacore et al. 2000) 
Alpha synuclein 
Intracellular alpha-synuclein accumulation in oligodendrocytes is the main 
pathological hallmark of MSA and it is reasonable to speculate that this 
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protein has a key role in the still almost completely unknown mechanisms of 
the disease. 
Alpha-synuclein is phisiologically expressed in neurons and in developing 
oligodendrocytes, whereas it is not expressed in mature oligodendrocytes. 
Therefore, the finding of the protein in these cells is difficultly comprehensible 
and many hypotheses have been formulated to explain the phenomenon.  
The first hypothesis suggests a reactivation of the expression of alpha-
synuclein gene (SNCA) in patients’ cells. In situ hybridization technique 
performed on brain samples of MSA patients and controls has not succeeded 
in detecting SNCA mRNA (Miller et al., 2005). Differently, a more recent 
study (Asi et al., 2014), based on qPCR, has found an increased expression 
of the gene in patients. 
A second plausible hypothesis is that alpha-synuclein is not directly 
translated in oligodendrocytes, but that it is taken up by these cells from 
surrounding neurons or from the extracellular environment. Interestingly, the 
possible transfer of alpha-synuclein both from-neuron-to-neuron (Desplats et 
al., 2009) and from-neuron-to-oligodendrocyte (Reyes et al., 2014) has been 
observed in vitro. In particular, oligodendrocytes have been treated with the 
monomeric, oligomeric and fibrillar forms of the protein and a concentration- 
and time-dependent cellular uptake has been observed. Furthermore, the 
injection of alpha-synuclein into mouse cortex has been found to be followed 
by in vivo oligodendroglial internalization. 
A third recent hypothesis suggests a prion-like behavior of alpha-synuclein 
in MSA (Woerman et al., 2015; Prusiner et al., 2015). 
An important issue related to alpha-synuclein pathology is to understand the 
cause which leads to accumulation specifically in oligodendrocytes. It has 
been proposed that the accumulation is triggered by specific oligodendroglial 
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proteins, with a particular focus on p25alpha/TPPP. As demonstrated co-
expressing TPPP and alpha-synuclein in rat oligodendrocytes, TPPP 
enhances alpha-synuclein aggregation. (Hasegawa et al., 2010) This 
observation is particularly interesting because TPPP has been demonstrated 
to be implicated in the early phase of MSA pathogenesis. In particular, TPPP 
relocation from myelin sheath to oligodendrocyte’s soma is the earliest 
pathological finding which has been observed in the progression of the 
disease. Only later, the accumulation of other proteins, including alpha-
synuclein, is observed in oligodendrocytes’ cytoplasm, followed by 
oligodendroglial and, finally, neuronal degeneration. (Jellinger, 2014)  
The relationship between anomalous protein accumulation and cellular 
degeneration is another important issue correlated with the pathogenic 
mechanisms of MSA. 
A role of both extrinsic and intrinsic apoptotic pathways has been postulated. 
As proposed in studies involving PLP-hasyn-tg-mice and MSA brain extracts, 
alpha-synuclein/TPPP co-expression leads to Fas receptor stimulation and 
Caspase 8 activation. (Kragh et al., 2013) Instead, the finding of the 
mitochondrial pro-apoptotic protein Omi/HtrA2 in GCIs, NCIs and dystrophic 
neurites is consistent with a possible involvement of the intrinsic apoptotic 
pathway. (Kawamoto et al., 2008) 
The relationship between oligodendroglial and neuronal degeneration is not 
clear yet. Although neuronal death usually follows oligodendroglial 
degeneration, it has not been demonstrated that the pathology starts from 
the glia and subsequently spreads to neurons. However, a suggestive 
hypothesis is that oligodendroglial degeneration triggers or at least facilitates 
neuronal damage. This hypothesis is supported by the fact that neurons need 
oligodendrocytes not only for the formation of the myelin sheath but also for 
their trophic support. It has been shown that oligodendroglial precursors and 
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mature oligodendrocytes release factors which support neuronal survival and 
axonal length. GDNF has been found to be reduced in the MBP-hasyn-tg-
mouse-model. Furthermore, intracerebroventricular GDNF infusion improves 
neurodegenerative pathology and behavioral deficit in these mice. (Wilkins 
et al., 2003; Ubhi et al., 2010) 
Inflammation 
Inflammation seems to play a crucial role in the pathogenesis of MSA. 
Microglial activtion is a common finding in MSA autoptic brain tissues. 
Microgliosis, together with an increase of iNOS (inducible nitric oxide 
synthase) expression can be detected also in MSA mouse models. It is 
possible that alpha-synuclein overexpression in oligodendrocytes induces 
nitrosative stress-related inflammation. Furthermore, also the expression of 
toll-like receptor 4 is increased both in tg-mouse models and in autoptic 
brains. (Stefanova et a., 2005; Stefanova et al., 2007) 
A possible role of alpha-synuclein in activating microglia through a toll-like 
receptor mediated pathway is supported by various studies. (Su et al., 2008; 
Su et al., 2009; Beraud et al., 2011; Beraud et al., 2013) Furthermore it has 
been shown that misfolded alpha-synuclein activates microglia inducing the 
production of the pro-inflammatory cytokine TNF-alpha and enhancing the 
expression of antioxidant enzymes.  
A possible role of myeloperoxidase is supported by the finding that the 
inhibition of this enzyme in MSA mouse models reduces microglial activation, 
rescues vulnerable neurons, reduces alpha-synuclein aggregates and 
reduces motor impairment. (Stefanova et al., 2012) 
Mitochondrial dysfunction 
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Mitochondrial dysfunction plays an important role in many 
neurodegenerative disorders, both as potential causative mechanism and as 
secondary effect. 
Mitochondrial involvement in alpha-synucleinopathies has been widely 
studied, mainly in Parkinson’s disease. (Schapira, 2008) Defect in complex I 
activity has been found in substantia nigra and other tissues of PD patients. 
(Schapira et al., 1989) Moreover, the administration of complex I inhibitors, 
namely MPTP and rotenone, to humans and animal models has been 
associated with striatonigral degeneration and/or parkinsonism. (Singer et 
al., 1986; Betarbet et al., 2000) Furthermore, an increased amount of mtDNA 
deletions has been observed in PD (Bender et al., 2006) and many of the 
genes involved in familial PD cases are directly or indirectly linked to 
mitochondrial functioning (e.g. Parkin, PINK1, DJ-1). 
However, some studies have been carried out also in MSA. An old study, 
aimed to assess the activity of respiratory chain complexes in substantia 
nigra and platelets of patients and controls, has not found significant 
differences between groups. (Gu et al., 1997) Instead, great interest has 
been raised by the recent description of mutatons of COQ2 gene (encoding 
an enzyme involved in CoQ10 biosynthesis) in sporadic and familial cases 
of MSA. (Multiple System Atrophy Research Collaboration, 2013) However, 
this finding has not been confirmed by other studies. (Sharma et al., 2014; 
Schottlaender et al., 2014; Ronchi et al., 2016) Moreover two independent 
groups have recently described a reduction of CoQ10 levels selectively in 
the cerebellum of MSA patients, but not in striatum, frontal cortex and 
occipital cortex. (Schottlaender et al., 2016; Barca et al., 2016) Furthermore, 
the amount of PDSS1 and COQ5, two enzymes involved in the synthesis of 
CoQ10 have been found to be reduced in MSA brains.     
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Induced pluripotent stem cells (iPSCs) 
“Stemness” is a relatively broad-spectrum concept referrable to a wide group 
of cellular subtypes which share two important abilities: self-replicating and 
differentiating. 
Several classes of stem cells can be found in the human organism and can 
be distinguished on the basis of their residual differentiative potential and of 
their location. In adult human tissues stem cells maintain a restricted 
differentiative potential, being able to differentiate only towards a certain 
class of mature cellular subtypes. For example, hematopoietic stem cells, 
routinarely used in clinical practice, have a differentiative potential almost 
restricted to blood cells and, similarly, epidermis basal layer cells are aimed 
to provide new precursors for the generation of mature keratinocytes. 
Although the nervous system is mainly composed of non-replicating cells, 
adult stem cells have been detected also in this area, but little is known about 
them (Alvarez-Buylla et al., 2002). 
Differently, in the first phase of embryonal development, it is possible to find 
cells which are able to differentiate towards all the cellular subtypes of the 
organism and, for this reason, are named pluripotent stem cells (PSCs).  
Embryonal stem cells (ESCs) have been the only available form of PSCs 
until a decade ago, when the generation of induced pluripotent stem cells 
(iPSCs) has been described (Takahashi and Yamanaka, 2006). 
iPSCs are not phisiologically present in the human organism but they are 
artificially produced in laboratory through the forced expression of specific 
factors, namely Sox2, Oct4, Klf4 and c-Myc. The expression of these factors 
reconducts adult somatic cells (e.g. skin fibroblasts) to a condition of 
pluripotency. The responsible mechanism has not been completely 
elucidated yet. Oct4 and Sox2 upregulate stemness genes and suppress 
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differentiation associated genes, acting synergistically (Boyer et al. 2005), 
whereas the role of Klf4 and c-Myc is less clear. However, it has been 
proposed that Oct4 and Sox2 cannot bind their target genes because of DNA 
methylation and histone modifications and it is possible that Klf4 and c-Myc 
modify chromatine structure, allowing the binding of Oct4 and Sox2. 
Although iPSCs’ generation has been described only a decade ago, they 
have already been used in a large number of studies and are promising for 
many reasons. iPSCs offer the potential to generate any kind of cellular 
population (even those which are hardly accessible in the human body, such 
as neurons and glia) just starting from a skin biopsy or a blood withdrawal. 
As these cells share the same genetic background of the subjects from whom 
they are derived, they can be useful to model genetic diseases or diseases 
in which a genetic predisposition is involved. Furthermore, iPSCs display a 
high potential in the field of therapeutics. Indeed, although much research is 
still needed, the advantage of replacing degenerated or damaged tissues 
with new cells directly derived from the patient is obvious and could 
potentially eliminate the problem of immunological reject.  (Shi et al., 2017) 
 
 
Differentiation of pluripotent stem cells to different cellular subtypes 
Pluripotent stem cells can be differentiated towards all the cellular subtypes 
of the organism, including neurons and glia.  
Differentiation protocols are now available for many cell types of the nervous 
system: dopaminergic neurons, cortical and spinal motor neurons, 
GABAergic neurons (Purkinje cells, medium spiny neurons, interneurons), 
astrocytes, oligodendrocytes and others. 
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Methods are heterogeneous and can involve culturing cells in adhesion or in 
suspension. Also the generation of three-dimensional structures called 
organoids has been recently described. 
Feasibilitty and efficiency are highly variable, too. 
However, all the protocols share the same rationale, that is the administration 
of specific factors, called morphogens, at specific timing and concentration, 
which mimic the physiological development of the nervous system (Liu et al., 
2011).  
Nervous system starts developing when the inner mass begins to form the 
three germ layers (endoderm, mesoderm and ectoderm). The nervous 
system originates from the ectoderm. Activation of fibroblast growth factor 
(FGF) and inhibition of bone morphogenetic protein (BMP) and WNT leads 
to the specialization of neuroectoderm. Two main axis, rostro-caudal and 
dorso-ventral, are involved in the development of the nervous system. 
All the central nervous system develops from primitive neuroepithelia, which 
carries a dorsal telencephalic identity.  
Different areas can be found along the rostro-caudal axis. Forebrain, from 
which telencephalon and diencephalon differentiate, is the most rostral zone. 
Midbrain is located under the forebrain. Hindbrain, more caudal, can be 
divided into metencephalon and myelencephalon. Pons and cerebellum 
originate from metencephalon, medulla oblongata originates from 
myelencephalon. Spinal cord is the most caudal structure. 
Also the dorso-ventral axis is important for cellular specification. 
In forebrain, glutamatergic pyramidal neurons are the most dorsal 
population. GABAergic projection neurons (from which striatal medium spiny 
neurons develop) and basal forebrain cholinergic neurons originate more 
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ventrally, whereas GABAergic interneurons originate along the entire dorso-
ventral axis. 
On a different level, lower motor neurons originate from the ventral part of 
the spinal cord. 
Being primitive neuroepithelia characterized by dorsal telencephalic 
features, the default fate of neural precursor cells is glutamatergic, leading 
to cells expressing cortical and dorsal markers like Pax6 and Tbr1. 
Retinoic acid is the main factor involved in rostro-caudal differentiation, being 
a concentration-dependent caudalizing factor. The administration of retinoic 
acid leads to the loss of anterior markers like Otx2 and Foxg1 and to the 
expression of posterior markers like Hoxb4, Hoxc5 and Hoxc8.  
Also the dorso-ventral axis is regulated by specific factors. WNT and sonic 
hedgehog (SHH) play an essential role, being WNT characterized by a 
dorsalizing activity and SHH by a ventralizing one. Indeed, SHH 
administration or WNT inhibition lead to the loss of the expression of the 
dorsal marker Pax6 and to the expression of ventral markers like Gsx2 and 
Nkx2.1.  (Liu et al. 2011) 
Glial differentiation is particularly long and complicated, in particular for 
oligodendrocytes. However, many protocols have been recently published, 
although with low efficiency rates. 
Differentiation towards dopaminergic neurons, which are the main object of 
the present study, requires a specific paragraph. 
 
 
Dopaminergic differentiation and iPSC-based models of Parkinson’s 
disease 
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Substantia nigra dopaminergic neurons represent a peculiar cellular 
population. 
PD has been widely modeled through iPSCs. The opportunity to assess not 
only sporadic but also genetic forms of the disease and the continuous 
improvement of dopaminergic neurons’ differentiation protocols has further 
encouraged the application of this technique. 
iPSC-based cellular models have been obtained from patients affected with 
sporadic forms of PD and from patients carrying mutations in LRRK2, SNCA, 
GBA, Parkin and PINK1 genes (e.g. Nguyen et al., 2011; Sanchez-Danes et 
al., 2012; Byers et al., 2011; Woodard et al., 2014; Schöndorf et al., 2014; 
Seibler et al., 2011; Rakovic et al., 2013; Imaizumi et al., 2012). 
The first protocols aimed to generate dopaminergic neurons were based on 
neural rosettes (Perrier et al., 2004) and were characterized by a relatively 
low efficiency. 
However, a new method, based on dual SMAD inhibition has been described 
(Kriks et al., 2011). All the protocol is performed in adhesion and allows to 
obtain dopaminergic neurons with high efficiency.  
The main rationale of the protocol is the observation that developing midbrain 
is characterized by the co-expression of the floor-plate marker FOXA2 and 
the roof plate marker LMX1A. Therefore, authors have developed a protocol 
leading to a balance of differentiation factors which allows to obtain this 
cellular identity. The procedure is based on different steps involving dual-
SMAD inhibition (administration of LDN193189 and SB431542), 
administration of SHH agonists (purmorphamine + SHH), administration of 
FGF8 and administration of CHIR. The authors also demonstrate that the 
lack of any of these compounds leads to a lower efficiency of differentiation. 
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The protocol that has been applied in the present study (Zhang et al., 2014) 
is a slight modification of Kriks’s protocol. 
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AIM OF THE STUDY 
The aim of the present study is the development and the analysis of new 
experimental models for the assessment of the pathogenic mechanisms of 
Multiple System Atrophy. 
The lack of an exhaustive and reliable model of the disease is the rationale 
for the investigation of several tissues and cellular subtypes. 
Both patient-derived fibroblasts, a cell type which is not directly affected in 
the disease but which can be easily withdrawn and expanded, and iPSC-
derived dopaminergic neurons, strongly affected but difficult to generate in 
laboratory, will be used to investigate the molecular mechanisms of the 
disease. The availability of DNA extracted from peripheral blood cells and 
post-mortem brain tissue of large cohorts of patients and controls will be 
exploited for the same purpose. 
The study will assess several topics, with a particular focus on three fields: 
alpha-synuclein, autophagy and mitochondrial functioning. 
Alpha-synuclein expression, accumulation and regulation, basal autophagy 
and autophagic flux, mitochondrial mass, respiratory chain activity, 
mitochondrial DNA content and CoQ10 biosynthesis are the main themes 
which will be investigated in this project. 
The present study will contribute to understand the molecular basis of the 
disease, so far widely unclear, and to lay the foundations for the future 
development of new therapeutic strategies. 
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MATERIALS AND METHODS 
Ethical issues 
All the phases of the present study were carried out in compliance with the 
principles of Helsinki Declaration. Informed consent was obtained from all 
the subjects and local ethical guidelines were observed. 
 
Diagnostic procedure 
Diagnosis of probable MSA was performed according to widely accepted 
clinical criteria (Gilman’s criteria). 
 
Skin biopsies and fibroblasts’ expansion 
Skin biopsies were obtained through a 3 mm punch from the ventral surface 
of the right arm after disinfection with lodopovidone and anesthesia with ice 
spray. Fibroblasts were isolated from biopsies and expanded in proper 
culture medium (Dulbecco’s modified Eagle medium supplemented with fetal 
bovine serum 15%, amphotericin B 1% and penicillin/streptomycin 1 %).  
The main details of all the subjects from whom skin biopsies were obtained 
are reported: 
 SEX AGE 
MSA-C1  n/a n/a 
MSA-C2 F 59 
MSA-C3  F 60 
MSA-C4  F 68 
MSA-C5  n/a n/a 
MSA-C6  F 70 
MSA-C7  F 66 
MSA-P1  F 80 
MSA-P2  F 66 
MSA-P3  F 61 
28 
 
MSA-P4  F 78 
MSA-P5  M 55 
MSA-P6  n/a n/a 
MSA-P7  F 77 
CTR1  F 40 
CTR2  M 44 
CTR3  F 106 
CTR4  M 57 
CTR5  M 60 
CTR6  M 65 
 
MSA-C1, MSA-C5 and MSA-P6 were obtained from a cell biobank and 
detailed information is lacking. 
 
Reprogramming of fibroblasts towards iPSCs 
Reprogramming of fibroblasts was obtained through the commercially 
available kit CytoTune®-iPS 2.0 Sendai Reprogramming Kit (Life 
technologies). This kit is based on a not-integrating viral method which allows 
the transfection of the factors Oct3/4, Sox2, Klf4 and c-Myc. After 1 week 
from reprogramming, fibroblasts were transferred to feeder-coated dishes. 
When iPSCs’ colonies appeared, they were transferred to matrigel-coated 
dishes and expanded.  
The main clinical features of all the subjects from whom iPSCs were 
generated are reported: 
 SEX AGE Corresponding 
fibroblast cell line 
MSA-C1 (AT) F 59 C2 
MSA-C2 F 60 C3 
MSA-P1  F 78 P4 
MSA-P2  M 55 P5 
CTR 1 M 24 / 
CTR 2 F 60 / 
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CTR 3 M 68 / 
CTR 4 F 80 / 
UT F 59 / 
 
Differentiation of iPSCs towards dopaminergic neurons 
An already described protocol was applied (with minor changes) for 
differentiation of iPSCs towards dopaminergic neurons (Zhang et al., 2014). 
The protocol is based on the administration of specific factors at proper 
timing and concentration - D0: KSR differentiation medium (DMEM 81%, 
KSR 15%, non-essential amino acids 1%, beta-mercaptoethanol 1%, 
penicillin(10000 units/ml)/streptomycin(10mg/ml) 1%, amphotericin 250 
μg/ml 1%) supplemented with SB431542 10 μM and LDN-193189 100nM. - 
D1 and D2: KSR differentiation medium supplemented with SB431542 10 
μM, LDN-193189 100nM, SAG 0.25 μM, purmorphamine 2 μM, FGF8b 50 
ng/ml - D3 and D4: KSR differentiation medium supplemented with 
SB431542 10 μM, LDN-193189 100nM, SAG 0.25 μM, purmorphamine 2 
μM, FGF8b 50 ng/ml, CHIR99021 3 μM - D5 and D6: 75% KSR differentiation 
medium and 25 % N2 differentiation medium (DMEM 97%, N2 supplement 
1%, penicillin/streptomycin 1%, amphotericin 1%) supplemented with LDN-
193189 100nM, SAG 0.25 μM, purmorphamine 2 μM, FGF8b 50 ng/ml, 
CHIR99021 3 μM - D7 and D8: 50% KSR differentiation medium and 50% 
N2 differentiation medium supplemented with LDN-193189 100nM and 
CHIR99021 3 μM - D9 and D10: 25% KSR differentiation medium and 75% 
N2 differentiation medium supplemented with LDN-193189 100nM and 
CHIR99021 3 μM - D11 and D12: B27 differentiation medium (Neurobasal 
medium 95%, B27 supplement 2%, glutamax 1%, penicillin/streptomycin 1%, 
amphotericin 1%) supplemented with CHIR99021 3 μM, BDNF 10 ng/ml, 
GDNF 10 ng/ml, TGFb3 1 ng/ml, ascorbic acid 0.2 mM, cAMP 0.1 mM - From 
D13 to the end of differentiation: B27 differentiation medium supplemented 
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with BDNF 10 ng/ml, GDNF 10 ng/ml, TGFb3 1 ng/ml, ascorbic acid 0.2 mM, 
cAMP 0.1 mM. At 20 DIV cells were splitted using accutase. 
 
Immunocytochemistry 
Slide-adherent cells were rinsed in PBS 1X (3 times), incubated in 
paraformaldehyde 4% for 10 minutes and rinsed in PBS 1X (3 times). Cells 
were then incubated in blocking solution (PBS 1X containing BSA 10% and 
triton 0.3%) for 1 hour and in saturation solution (PBS 1X containing BSA 
3%) containing primary antibody at proper concentration overnight at 4 °C. 
Cells were then incubated in saturation solution containing secondary 
antibody and DAPI at proper concentration for 2 hours and rinsed in PBS 1 
X (3 times). Finally, the slides were mounted. The confocal system Leica 
TCSSP2 (Leica Microsystems) was used for images acquisition.  
Details about antibodies are indicated in the following table. 
Antibody Manufacturer Code Dilution 
Pluripotent Stem Cell 4-
Marker 
Immunocytochemistry 
Kit 
Thermo Fisher A24881 1:100 
TUJ1 Abcam ab18207 1:250 
TH R&D Systems MAB7566 20 µg/ml 
TH Thermo Scientific PA5-17800 1:100 
GIRK2 Abcam ab65096 1:100 
MAP2 Sigma-Aldrich M9942 1:100 
Alexa 488 anti-mouse Life Technologies A11001 1:500 
Alexa 488 anti-goat Jackson 
ImmunoResearch 
705-545-003 1:500 
Alexa 488 anti-rabbit Life Technologies A11034 1:500 
Alexa 568 anti-mouse Life Technologies A11004 1:500 
Alexa 568 anti-rabbit Life Technologies A11011 1:500 
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Western Blot 
Proteins were extracted in H2O + protease inhibitor cocktail (P2714, Sigma), 
sonicated 2 times for 15 seconds at 50 W and centrifuged for 10 minutes at 
750 g. Proteins were quantified through the Lowry method. Samples were 
prepared in Novex Bolt LDS sample buffer and Novex Bolt Reducing Agent 
(Thermo Fisher) and boiled for 3 minutes. 5-30 μg of proteins were loaded in 
Precast Bolt® Bis-Tris Plus Gels 4-12 % and in Novex Bolt 1X MES/SDS 
Running buffer at 200 V for 30 minutes. Trans-Blot® Turbo™ system 
(BioRad) was used for transfer in nitrocellulose membrane. Membranes were 
blocked with milk 5% (BioRad) or BSA 1% + horse serum 10%. HRP 
secondary antibodies were used (Dako) and protein bands were visualized 
through ECL. ImageJ (NIH) was used for bands intensity quantification. 
Protein amount was normalized for Actin, GAPDH or Vinculin. 
Details about antibodies are indicated in the following table. 
Antibody Manufacturer Code Dilution 
TUJ1 Sigma T8660 1:1000 
Alpha-synuclein BD transduction 
laboratories 
610787 1:1000 
Bax Cell Signaling 2772 1:1000 
Bcl-2 Abcam ab32124 1:1000 
Cleaved Caspase 3 Cell Signaling 9661 1:1000 
LAMP1 Abcam ab25630 1:875 
P62 Millipore MABN130 1:1200 
Cathepsin D Santa Cruz SC-6486 1:1000 
LC3 Cell Signaling 2775 1:1000 
TOMM20 Sigma HPA011562 1:750 
OXPHOS (containing 
antibodies detecting 
NDUFB8, SDHB, UQCRC2, 
MTCO2 and ATP5A) 
Abcam ab110411 1:1000 
SDHA Invitrogen 459200 1:1000 
COX1 Invitrogen 459600 1:1000 
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COX4 Invitrogen A21347 1:1000 
TH Millipore AB152 1:2000 
TAU Cell Signaling 4019 1:1000 
Synaptophysin Synaptic System 101011 1:5000 
Synapsin I Synaptic System 106103 1:2000 
Synapsin III Synaptic System 106303 1:2000 
ADCK3/CABC1 Thermo Scientific PA5-13906 1:1000 
PDSS1 Sigma AV46195 1:1000 
PDSS2 Abcam ab88817 1:1000 
COQ2 Abnova H00027235-M03 1:1000 
COQ4 Abcam ab167182 1:1000 
COQ5 Thermo Scientific PA5-26327 1:1000 
COQ6 Abcam ab128652 1:1000 
COQ7 Thermo Scientific PA5-25774 1:1000 
COQ9 Thermo Scientific  PA5-24816 1:1000 
Actin Sigma A2066 1:1200 
Vinculin Abcam ab18058 1:5000 
GAPDH Sigma-Aldrich G8795 1:5000 
Secondary mouse HRP Dako P0260 1:3200 
Secondary rabbit HRP Dako P0217 1:2700 
Secondary goat HRP Dako P0160 1:4000 
Secondary mouse HRP Sigma A0545 1:2000 
Secondary rabbit HRP Sigma A9044 1:2000 
   
 
DNA and RNA extraction from cells and reverse transcription 
DNA and RNA were extracted through commercially available kits 
(FlexiGene DNA Kit, Qiagen and RNeasy Mini Kit, Qiagen, respectively) 
according to the manufacturer’s instructions. A Nanodrop spectrophotometer 
was used to measure DNA and RNA concentration.  
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cDNA was obtained through the commercially available kit “Ready-To-Go 
You-Prime First-Strand Beads” (GE Healthcare), using 1 µg of RNA for each 
sample. 
 
qPCR 
For each well, 25 µl were prepared as follows: - Taqman: 12.5 µl of 
TaqMan Universal PCR Master Mix (Thermo Fisher), 6.5 µl of H20, 1 µl of 
primer/probe assay, 5 µl of 1:10 dilution of cDNA - SYBRgreen: 12.5 µl of 
Power SYBR® Green PCR Master Mix (Applied Biosystems), 5 µl of 1:10 
dilution of cDNA, forward and reverse primers at proper concentration and 
H2O up to a total volume of 25 μl.  18S, ACTB and GAPDH were used as 
housekeeping genes. Analyses were performed with the ΔΔCt method. A 
7500 Real Time PCR System was used. For the mtDNA content evaluation 
genomic DNA was used, simultaneously detecting a mitochondrial gene 
and a nuclear reference gene (ND4 vs RNaseP, ND1 vs RNaseP or CytB 
vs APP). The ΔΔCt method was used for analyses.  
 
Karyotype Analysis 
After adding colchicine to culture, iPSCs were processed with a hypotonic 
solution (0.6% sodium citrate and 0.13% potassium chloride) and fixed with 
methanol/acetic acid solution at 3:1 ratio. Q-banding was obtained through a 
Quinacrine solution. Metaphases were acquired with a fluorescence 
microscope at 100X magnification and analyzed with MetaSystems-Ikaros 
analytical system.  
 
Spectrophotometric analyses 
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Respiratory chain complexes activities were measured through a Lambda 2 
Parkin Elmer spectrophotometer. Proteins were extracted at 4 °C by adding 
a buffer at pH 7.2 to cell pellets, sonicating 3 times at 50 W for 10 seconds, 
centrifuging at 750 g for 10 minutes and recovering the supernatant. Protein 
concentration was measured through the Lowry method. Complex I activity 
(NADH ubiq.1 red) was measured at 340 nm after preparing a solution 
containing: K-phosphate pH 7.5 0.1M (200 µl), sodium azide 100 mM (10 µl), 
albumin 1% (100 µl), NADH 2mM (70 µl), H2O (610 µl), homogenate (10 µl), 
CoQ1 6mM (5 µl); afterwards rotenone 1mM (5 µl) was added and the 
residue activity was subtracted from the total. Complex II activity (Succ. Coq. 
Red) was measured at 600 nm after preparing a solution containing: K-
phosphate pH 7 0.1M (500 µl), succinic acid 400 mM (40 µl), 2,6 
dichloroindophenol 0.5 mM (200 µl), KCN 30mM (50 µl), H2O (190 µl), 
homogenate (20 µl), CoQ1 15 mM (3 µl). Complexes I+III activity (NADH cit 
C red) was measured at 550 nm after preparing a solution containing: K-
phosphate pH 7.5 0.1M (250 µl), KCN 30mM (20 µl), NADH 2 mM (120 µl), 
cytochromeC 1mM (100 µl), homogenate (20 µl), H2O (490 µl). Complexes 
II+III activity (Succ cit C red) was measured at 550 nm after preparing a 
solution containing: K-phosphate pH 7.5 0.1M (500 µl), KCN 30 mM (20 µl), 
succinate 400 mM (50 µl), cytochromeC 1 mM (100 µl), homogenate (30 µl), 
H2O (300 µl). Complex IV activity (Cytochrome ox) was measured at 550 nm 
after preparing a solution containing: K-phosphate pH 7 0.1M (200 µl), 
reduced cytochromeC 1% (100 µl), H2O (680 µl), homogenate (20 µl). Citrate 
synthase activity was measured at 412 nm after preparing a solution 
containing: DTNB 1 mM (100 µl), oxaloacetic acid 10 mM (50 µl), AcetylCoA 
10 mM (30 µl), H2O (800 µl), homogenate (20 µl). All the experiments were 
performed at 30 °C. All the activities were normalized for the activity of citrate 
synthase.  
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Sphingolipids analyses 
Neurons were incubated with 3×10-8 M [1-3H]sphingosine for a 2 hours pulse 
followed by a 48 hours chase. After harvesting, cell lysates were lyophilized 
and lipids were extracted with chloroform/methanol/water 2:1:0.1. Total lipid 
extracts were subjected to a two-phase partitioning, resulting in the 
separation of an aqueous phase containing gangliosides and in an organic 
phase containing all other lipids. Organic phases were subjected to an 
alkaline treatment aimed to remove glycerophospholipids. High performance 
thin layer chromatography was used for lipid extraction using the solvent 
systems chloroform/methanol/water 110:40:6 and 
chloroform/methanol/calcium chloride 0.2% 50:42:11 for the alkali-stable 
organic and the aqueous phases respectively. Digital autoradiography was 
used to detect and quantify radioactive lipids (Beta-Imager 2000 instrument, 
BioSpace). Lipids were identified by co-migration with authentic standards. 
M3Vision software was used to determine the radioactivity associated with 
individual lipids. Liquid scintillation counting was used to determine the 
radioactivity associated with lipid extracts and aqueous or organic phases. 
 
Lysosomal enzymatic activity assays 
The fluorogenic substrates used to determine the activities of lysosomal 
enzymes were purchased by Glycosynth: 4-Methylumbelliferyl β-D-
glucopyranoside (MUB-β-Gluc) for β-glucocerebrosidase GBA1, 4-
Methylumbelliferyl β-D-galactopyranoside (MUB-β-Gal) for β-galactosidase, 
4-Methylumbelliferyl N-acetyl-β-D-glucuronide (MUG) for β-hexosaminidase, 
4-Methylumbelliferyl α-D-mannopyranoside (MUB-α-Man) for α-
mannosidase, 4-Methylumbelliferyl β-D-mannopyranoside (MUB-β-Man) for 
β-mannosidase. 6-hexadecanoylamino 4-MU-phosphoryl-choline (HMU-PC) 
(Moscerdam Substrates) was used for measuring sphingomyelinase activity. 
iPSC-derived neurons were harvested and lysed in water containing 
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protease inhibitors. The activities of β-galactosidase, β-hexosaminidase, α-
mannosidase, β-mannosidase and sphingomyelinase were measured in 
McIlvaine Buffer pH 5.2 using 0.5 mM MUB-β-Gal, 0.5 mM MUG, 0.5 mM 
MUB-α-Man, 0.5 mM MUB-β-Man and 0.25 mM HMU-PC, respectively. For 
GBA1 assay, the cells were pre-incubated for 30 min at room temperature in 
McIlvaine containing 5 nM AMP-DNM N-(5-adamantane-1-yl-methoxy-
pentyl)-deoxynojirimycin), specific inhibitor of GBA2. After incubation with the 
inhibitor, MUB-β-Gluc was added at a final concentration of 6 mM. The 
reaction mixtures were incubated at 37 °C under gentle shaking. The 
fluorescence was recorded after transferring 10 μl of the reaction mixtures to 
a microplate and adding 190 μl of 0.25 M glycine, pH 10.7. 
 
Electrophysiology  
Currents and Action Potentials, recorded in whole-cell configuration, were 
measured using an Axopatch 200B Amplifier and pClamp 10.2 software 
(Molecular Devices). Traces were sampled at 10 KHz using a Digidata 1322A 
acquisition Interface (Molecular Devices) and filtered at 1 KHz. Borosilicate 
glass pipettes were filled with a solution containing K-gluconate 126 mM, 
NaCl 4 mM, HEPES 10 mM, Glucose 10 mM, MgSO4 1 mM, CaCl2 0.5 mM, 
EGTA 1 mM, ATP (magnesium salt) 3 mM, GTP (sodium salt) 0.1 mM, pH 
7.2. External solution contained NaCl 140 mM, KCl 3 mM, MgCl2 1.2 mM, 
CaCl2 2 mM, HEPES 10 mM, Glucose 10 mM, pH 7.4. Action potentials were 
recorded in current-clamp mode, setting membrane potential at -65 mV and 
injecting 5 pulses of increasing intensity. Spontaneous action potentials were 
measured at resting membrane potential, without injecting currents. Voltage-
dependent ionic currents were recorded clamping cell membrane potential 
at -70 mV and delivering voltage steps lasting 800 ms and ranging from -80 
mV to 60 mV at 20 mV increments. 
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Methylation assay by mass array 
Five-hundred ng of genomic DNA were treated with sodium bisulphite using 
the EZ - DNA Methylation-Gold™ Kit (Zymo-Research, Irvine, CA), following 
the manufacturer’s instructions. The massARRAY EpiTYPER technology 
(Agena Bioscience, Hamburg, Germany) was used to measure the 
methylation status of 10 CpG units (i.e. regions containing one or multiple 
CpG sites), containing 17 CpG sites, within the SNCA promoter region (chr4: 
90,757,297 – 90,757,684). 15 ng of bisulphite-treated DNA were PCR-
amplified using the following primers: Fw: 5’ – 
aggaagagagTAAGGGTTGAGAGATTAGGTTGTTT – 3’; Rev: T7R, 
cagtaatacgactcactatagggagaaggctCAAACAAACAACAAACCCAAATATAA. 
Primers were designed by the EpiDesigner software (Agena), with the 
reverse primer containing a T7 promoter tag. The PCR reaction conditions 
were: 94°C for 4 min, followed by 45 cycles at 94°C for 20 sec, 56°C for 
30 sec, and 72°C for 1min.  After shrimp alkaline phosphatase treatment, to 
discard unincorporated DNA nucleotides, the T7 tag added during PCR was 
used to transcribe the PCR product from the reverse strand, yielding a single 
stranded RNA product. This RNA product was cleaved with RNase A, 
resulting in a specific fragmentation of the RNA product. Finally, samples 
were loaded on a 96-pad SpectroCHIP (Agena Bioscience), spectra were 
acquired by the MassARRAY Analyzer and methylation data of individual 
units were generated by the EpiTyper v1.0.5 software (Agena Bioscience). 
A single experiment was performed for each cell line. 
 
 
CoQ10 dosage 
CoQ10 was extracted with the hexane/ethanol 5:2 extraction technique. The 
hexane extract was dried under slow N2 gas flow and resuspended in 1-
propanol. CoQ10 levels were assessed by HPLC on a reverse-phase 
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Symmetry® C18 3.5 mm, 4.6 × 150 mm column, using a mobile phase 
consisting of methanol, ethanol, 2-propanol, acetic acid (500:500:15:15), and 
50mM sodium acetate at a flow rate of 0.9 ml/min. The electrochemical 
detection system consisted of an ESA Coulochem III with a guard cell 
(upstream of the injector) at +900 mV, conditioning cell at 600 mV 
(downstream of the column), followed by the analytical cell at +500 mV. 
Standard peaks were used to estimate CoQ10 concentration. 
 
Oxygraph 
A high-resolution respirometry Oxygraph-2k (Oroboros Instruments, 
Innsbruck, Austria) was used for respirometry analyses on fibroblasts. For 
each analysis, 800000 cells were resuspended in proper medium (MiRO5) 
and injected into the instrument’s chambers. Oxygen flux was measured at 
basal level and after the progressive administration of several compounds: 
digitonine, malate + glutamate, ADP, succinate, FCCP, rotenone and 
antimycin A. The value obtained after Antimycin A administration was 
subtracted to all other values. This experimental procedure was applied to 
assess basal respiration, complex I-related respiration, complex II-related 
respiration, maximal respiration, complex II-dependent maximal respiration. 
Values are expressed as pmol/(s x mL). 
 
Bafilomycin and CCCP treatment 
Cells were treated with bafilomycin at 200 nM for 24 hours.  
Cells were treated with CCCP at 40 µM for 6 and 14 hours. 
 
Statistical analyses 
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A two-tail Student’s T test was used for comparisons between two groups. A 
one way ANOVA test was used for comparisons involving more than two 
groups.   
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RESULTS 
Analyses on fibroblasts 
Several experiments were performed on 20 fibroblast cell lines (7 MSA-C, 7 
MSA-P and 6 healthy controls) to assess cell survival, autophagy and 
mitochondrial functioning. 
Apoptosis  
To investigate whether patients’ and controls’ fibroblasts displayed a different 
survival rate, the amount of the apoptosis-related proteins Bax (pro-
apoptotic), Bcl-2 (anti-apoptotic) and cleaved Caspase3 (pro-apoptotic) was 
assessed through western blot. No significant differences were detected 
between patients and controls. 
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Fig.1   
WB assessing the amount of the apoptosis-related markers Bcl2, Bax, cleaved Caspase 3 and Actin in MSA and control 
fibroblasts and related graph (values normalized for Actin). 
41 
 
Autophagy 
As a defect in the autophagic flux has been described in all alpha-
synucleinopathies, the amount of autophagy-related proteins LAMP1, 
Cathepsin D, p62 and LC3 was assessed through WB before and after the 
administration of bafilomycin, a V-ATPase inhibitor that causes the block of 
the fusion between the autophagosome and the lysosome. No significant 
differences were observed between patients and controls, neither at basal 
level, nor measuring the autophagic flux (bafilomycin-treated/basal ratio). 
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Fig. 2 
Autophagy in fibroblasts. WB assessing the amount of LAMP1, Cathepsin D, p62, LC3 and Actin in MSA and control fibroblasts 
before (-) and after (+) the administration of bafilomycin (200 nM, 24 h). 
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Mitochondrial functioning 
Spectrophotometric analyses showed an impaired activity of respiratory 
chain complexes. In particular, the activity of complexes II and II+III were 
significantly reduced in patients compared to controls. 
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Fig. 3  
Autophagy in fibroblasts. Graphs showing WB quantification. A) Basal amount of the autophagy-related proteins 
LAMP1, LC3 II, p62 and Cathpesin D (all normalized for Actin) in MSA and control fibroblasts. B) Autophagic flux 
measured as the ratio between the level of the autophagy-related proteins LAMP1, LC3 II, p62 and Cathepsin D 
after bafilomycin administration and their basal level. 
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Fig. 4  
Graph showing the activity level of respiratory chain complexes I, II, I+III, II+III and IV in MSA 
and control fibroblasts, measured through spectrophotometric analyses. Values are 
normalized for the activity of the mitochondrial matrix enzyme citrate synthase. 
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Western Blot analyses, aimed to assess the amount of respiratory chain 
complex I, complex II (SDHA and SDHB), complex III, complex IV and 
complex V, showed a trend of reduction in patients, significant for complex 
II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
qPCR, aimed to assess mtDNA content and performed through the 
simultaneous analysis of the mitochondrial gene ND1 and the nuclear 
SDHA 
Complex V 
Complex III 
SDHB 
Complex IV 
Complex I 
SDHA 
Complex V 
Complex III 
SDHB 
Complex IV 
Complex I 
Actin Actin 
0
0,5
1
1,5
2
complex I SDHA SDHB complex III complex IV complexV
n
o
rm
 A
ct
in
WB respiratory chain complexes
controls MSA
*
Fig. 5 
Respiratory chain complexes in fibroblasts. WB assessing the amount of SDHA, complex V, complex III, SDHB, complex 
IV, complex I and Actin in MSA and control fibroblasts and related graph (values normalized for Actin). 
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reference gene RNaseP, did not show statistically significant differences 
between patients and controls. 
 
 
 
 
 
  
 
Oxygen consumption, measured through high resolution respirometry 
(Oxygraph), was assessed at basal level and after the serial administratrion 
of specific compounds: digitonin, malate+glutamate, ADP, succinate, FCCP 
and rotenone. No significant differences were detected between patients 
and controls, although a trend of reduction was observed at maximal 
respiration rate in patients.  
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Fig. 6 
Graphs showing mtDNA content in MSA and control fibroblasts measured 
by qPCR through the simultaneous detection of the mitochondrial gene 
ND1 and the nuclear reference gene RNaseP. 
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Fig. 7 
Oxygen consumption in fibroblasts. Oxygen consumption in MSA and control fibroblasts 
measured through Oxygraph at basal level and after the administration of digitonin, 
malate+glutamate, ADP, succinate, FCCP and rotenone. Values are expressed in pmol/(s*ml) 
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To evaluate mitophagy, the amount of the mitochondrial proteins COX IV, 
TOMM20, SDHA and Porin was measured through WB at basal level and 
after 6 and 14 hours from the administration of the mitochondrial membrane 
uncoupler CCCP (40uM), which has been demonstrated to trigger the 
mitophagic pathway.  A lower reduction of all the markers was observed in 
patients after 14 hours from CCCP administration, reaching significance for 
COX IV. 
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Fig. 8  
Mitophagy in fibroblasts. WB assessing the amount of the 
mitochondrial proteins SDHA, porin, COX IV and TOMM20 
and of Actin at basal level and 6 and 14 hours after the 
administration of the mitochondrial membrane depolarizer 
and mitophagic inductor CCCP (40 µM) in MSA and control 
fibroblasts. 
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Analyses on iPSC-derived neurons 
Generation and characterization of iPSCs 
iPSCs were generated through a non-integrating viral protocol from 
fibroblasts of 2 MSA-C, 2 MSA-P, 4 healthy controls and the healthy 
monozygotic twin of one of the patients. 
Phase contrast microscope showed typical pluripotent stem cell colonies. 
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Mitophagy in fibroblasts. 
Graphs showing 
quantification of WB 
assessing the amount of 
SDHA, Porin, COX IV and 
TOMM20 (normalized for 
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Fig. 10 
Phase contrast microscope images 
showing the morphology of iPSC-
colonies of two patients (MSA-C1 
and MSA-P1). 
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The expression of specific markers was evaluated to assess the efficiency of 
the reprogramming process. 
ICC analyses showed a high expression of the stemness markers TRA-1-60, 
SSEA-4, OCT4 and SOX2 in all iPSC-lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
SA
-C
1 
M
SA
-P
1 
C
TR
1
 
SSEA-4 TRA-1-60 MERGE 
Fig. 11 
ICC assessing the expression of the pluripotency markers SSEA-4 (green) and TRA-1-60 (red) in three iPSC-lines (MSA-C1, 
MSA-P1 and CTR1). Scalebar = 75 μm 
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RT-PCR analyses confirmed high expression levels of the stemness-related 
genes NANOG and OCT4 respect to fibroblasts.  
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Fig. 12 
ICC assessing the expression of the pluripotency markers SOX2 (green) and OCT4 (red) in three iPSC-lines (MSA-C1, MSA-
P1 and CTR1). Scalebar = 75 μm 
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The presence of major genetic rearrangements due to the reprogramming 
process was ruled out through karyotype evaluation. 
 
 
 
 
 
 
 
 
 
Generation and characterization of iPSC-derived dopaminergic neurons 
As dopaminergic neurons are strongly affected in MSA, all iPSC lines were 
differentiated towards this neuronal subtype, following an already described 
protocol (Zhang et al., 2014). 
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Karyotype analyses of three iPSC-lines 
(MSA-C1, MSA-P1 and CTR1) excluding 
major genetic rearrangements due to 
the reprogramming process. 
Fig. 13 
iPSCs characterization. Graph showing high expression levels of the pluripotency 
markers NANOG and OCT4 in iPSCs respect to fibroblasts measured through qPCR. 
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The effectiveness of the differentiation protocol was assessed through ICC 
by evaluating the expression of specific markers at different time-points. 
At 35 days in vitro (DIV) more than 75 % of differentiating cells expressed 
the neuronal marker Tuj1 and at least 55 % of Tuj1-positive cells also 
expressed the catecholaminergic marker TH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At 50 DIV the expression of the neuronal marker MAP2 was expressed in at 
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Fig. 15 
ICC assessing the expression of the neuronal marker Tuj1 (red) and of the catecholaminergic marker TH 
(green) in three lines of iPSC-derived neurons (MSA-C1, MSA-P1 and CTR1) at 35 DIV. Scalebar = 50 μm 
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Furthermore, at 70 DIV more than half of TH-positive cells also expressed 
the marker GIRK2 which identifies neurons of midbrain area A9, involved in 
the striatonigral pathway. 
 
 
 
 
 
 
 
The expression of specific markers was also assessed through RT-PCR at 
35 DIV. The neuronal markers TUBB3 and MAP2 and the catecholaminergic 
marker TH were highly expressed respect to fibroblasts and iPSCs. 
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Fig. 16 
ICC assessing the expression of the neuronal marker MAP2 in three lines of iPSC-derived neurons (MSA-C1, MSA-P1 and 
CTR1) at 50 DIV. Scalebar = 75 μm 
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Fig. 17 
ICC assessing the expression of the catecholaminergic marker TH (red) and of the midbrain area A9 marker GIRK2 
(green) in one line (MSA-P1) of iPSC-derived neurons at 70 DIV. Scalebar = 75 μm 
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The expression of the neuronal marker Tuj1 at 35 DIV was also assessed 
through western blot, demonstrating a high protein amount respect to 
fibroblasts.  
 
 
 
 
 
 
As firing activity is an important feature of fully differentiated neurons 
electrophisiological analyses were performed.  
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Fig. 18 
Graphs showing high expression level of the 
neuronal markers TUBB3 and MAP2 and of the 
catecholaminergic marker TH in iPSC-derived 
neurons respect to fibroblasts and iPSCs 
measured through qPCR. 
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Fig. 19 
WB assessing the amount of the neuronal marker Tuj1 and of 
Actin in iPSC-derived neurons and in one fibroblasts line. 
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Inward and outward currents were recorded at 56 DIV. Spontaneous firing 
activity and evoked action potentials were observed at the same 
differentiation step. Only a few spikes of low amplitude were observed when 
assessing post-synaptic potentials at 70 DIV. 
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Fig. 20 
Electrophysiological analyses assessing the presence of inward and outward currents (56 DIV), spontaneous firing 
activity (56 DIV), evoked action potentials (56 DIV) and post-synaptic potentials (70 DIV) in iPSC-derived neurons. 
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To further characterize neurons, the lipidic pattern of three cell lines (MSA-
C2, MSA-P2 and CTR1 was assessed at 35 and 70 DIV. Despite the 
presence of a certain amount of the simple gangliosides GM3 and GD3, 
differentiating lines displayed high levels of all the polysialogangliosides 
detectable in mature nervous system. Notably, patients’ neurons displayed 
higher levels of GlcCeramide and LacCeramide and lower levels of Ceramide 
respect to control. 
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Fig. 21 
Autoradiography assessing the amount of the lipids GM3, GM2, GM1, GD3, GD1a, GD1b, 
GT1b, GQ1b in three lines (MSA-P2, MSA-C2 and CTR1) of iPSC-derived neurons at 35 and 
70 DIV. 
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Apoptosis and neuronal survival 
The amount of the apoptotic markers Bax (pro-apoptotic), Bcl2 (anti-
apoptotic) and cleaved Caspase 3 (pro-apoptotic) was assessed through WB 
in neurons at 35 DIV. No significant differences were observed, although a 
trend of increase of cleaved Caspase 3 could be observed both in MSA group 
and in the affected twin. 
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Fig. 22 
Autoradiography assessing the amount of the lipids Ceramide, Glucosylceramide, 
Lactosylceramide, Globosides and Sphyngomyelin in three lines (MSA-P2, MSA-C2 
and CTR1) of iPSC-derived neurons at 35 and 70 DIV. 
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The amount of various neuronal, axonal and synaptic markers was assessed 
through WB at 35 and 70 DIV to evaluate neuronal survival and integrity 
during differentiation: TH (dopaminergic marker), tau and phospho-tau 
(axonal markers), synapsin I, synapsin III and synaptophysin (synaptic 
markers). No significant results were obtained at 35 DIV. At 70 DIV neuronal 
markers were more expressed than at 35 DIV; no major differences were 
observed between groups and between twins in the amount of phospho-tau, 
synapsin III and synaptophysin, whereas TH, tau and synapsin I proved to 
be strongly reduced both in MSA group and in the affected twin. 
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Fig. 23 
Apoptosis in neurons. WB assessing the amount of the apoptosis-related markers Bax, Bcl2, cleaved 
Caspase 3 and of Actin in MSA and control iPSC-derived neurons at 35 DIV and related graphs (values 
normalized for Actin). 
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Fig. 24 
WB assessing the amount of the proteins TH, TAU, phospho-TAU, Synapsin I, 
Synapsin III and GAPDH in MSA and control iPSC-derived neurons at 35 DIV and 
related graphs (values normalized for GAPDH) 
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Fig. 25  
WB assessing the amount of the proteins TH, TAU, phospho-TAU, Synaptophysin, Synapsin I, 
Synapsin III and GAPDH in MSA and control iPSC-derived neurons at 70 DIV and related graphs 
(values normalized for GAPDH). 
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qPCR showed that tau protein reduction in patients and in the affected twin 
was not due to a decreased gene expression level. Not only MAPT 
expression was not reduced, but it was even increased in patients and in the 
affected twin at both time-points. 
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Fig. 26 
Graphs showing MAPT gene expression level in MSA and control iPSC-derived 
neurons at 35 and 70 DIV measured through qPCR. 
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Alpha-synuclein 
As alpha-synuclein accumulation is the most important neuropathological 
hallmark of MSA, several experiments were carried out to assess its 
expression. 
WB, performed at 35 and 70 DIV, did not detect any difference neither 
between patients and controls, nor between the twins in the amount of the 
monomeric form of the protein. 
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Fig. 27 
Alpha-synuclein in neurons. WB assessing the amount of alpha-synuclein and Actin in MSA and control iPSC-derived neurons 
at 35 and 70 DIV and graphs showing related quantification (values normalized for GAPDH). 
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qPCR showed a higher level of SNCA transcript in controls at 35 DIV and in 
patients at 70 DIV. Twins showed a higher SNCA mRNA level in the 
unaffected at both time-points. 
             
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further assess alpha-synuclein expression, various mechanisms of gene 
expression regulation were evaluated: the expression level of the 
transcription factor GATA2 and the methylation pattern of SNCA intron 1. 
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Fig. 28 
Graphs showing SNCA gene expression level in MSA and control iPSC-derived 
neurons at 35 and 70 DIV. 
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qPCR demonstrated a higher expression level of GATA2 both in controls and 
in the healthy twin at 35 DIV. Differently, at 70 DIV no differences were 
observed between MSA and control groups and a higher expression level 
was found in the affected twin respect to the unaffected. 
            
              
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass array technique allowed to investigate the methylation pattern of a CpG 
island located in SNCA intron 1. The patients’ group displayed a generalized 
hypomethylation pattern, consistent with the increased gene expression 
levels at 70 DIV, which reached statistical significance in three sites. Also the 
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Fig. 29 
Graphs showing GATA2 gene expression level in MSA and control iPSC-
derived neurons at 35 and 70 DIV. 
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affected twin displayed a lower degree of methylation respect to the 
unaffected. 
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Fig. 30 
Graphs showing the methylation pattern of a CpG island located in SNCA intron 1 in MSA and control 
iPSC-derived neurons at 35 DIV measured through mass array. 
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Autophagy 
The amount of the autophagy-related proteins LAMP1, Cathepsin D, p62 and 
LC3 was assessed through WB at basal level and after bafilomycin 
administration at 35 DIV. No significant results were observed for LAMP1, 
Cathepsin D and p62, whereas LC3 analyses showed remarkable signs of 
autophagic impairment: an increased basal level of LC3II and a reduced 
autophagic flux, both in MSA group and in the affected twin. 
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Fig. 31 
Autophagy in neurons. WB assessing the amount of LAMP1, Cathepsin D, p62, LC3 and Actin in MSA and control iPSC-derived 
neurons at 35 DIV before (-) and after (+) the administration of bafilomycin (200 nM, 24 h). 
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To further assess autophagy, the activity of the lysosomal enzymes GBA, α-
Mannosidase, β-Mannosidase, β-Hexosaminidase, β-Galactosidase and 
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Fig. 32 
Graphs showing quantification of basal amount of the autophagy-related proteins LAMP1, LC3 II, p62 and Cathpesin D (all 
normalized for Actin) in MSA and control neurons. 
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Fig. 33 
Graphs showing quantification of the autophagic flux in neurons, measured as the ratio between the level of the autophagy-
related proteins LAMP1, LC3 II, p62 and Cathepsin D after bafilomycin administration and their basal level. 
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Sphingomyelinase was measured at 35 DIV. α-Mannosidase and β-
Mannosidase showed a significantly reduced activity level both in the MSA 
group and in the affected twin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
R
el
at
iv
e 
ac
ti
vi
ty
Lysosomal enzymes activity
controls MSA
*** ***
0
0,5
1
1,5
2
2,5
R
el
at
iv
e 
ac
ti
vi
ty
Lysosomal enzymes activity twins
UT AT
*
*
*
***
Fig. 34 
Graphs showing the activity level of the lysosomal enzymes GBA1, α-Mannosidase, β-Mannosidase, 
β-Hexosaminidase, β-Galactosidase and Sphingomyelinase in MSA and control neurons at 35 DIV. 
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Mitochondrial functioning 
Spectrophotometric analyses, performed at 35 DIV, showed a reduced 
activity of respiratory chain complexes in MSA group (significant for 
complexes II+III) and in the affected twin (significant for complexes II and 
II+III).  
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Fig. 35 
Graphs showing the activity level of respiratory chain complexes I, II, I+III, II+III and IV in MSA and 
control iPSC-derived neurons at 35 DIV, measured through spectrophotometric analyses. Values 
are normalized for the activity of the mitochondrial matrix enzyme citrate synthase. 
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The amount of the structural mitochondrial protein TOMM20 was assessed 
through WB and normalized for Actin in order to estimate mitochondrial 
content in cells. TOMM20 was significantly increased in MSA group and a 
trend of increase was observed also in the affected twin. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
The amount of all the complexes of respiratory chain was measured 
through WB and normalized for the mitochondrial structural protein 
TOMM20: complex I, complex II (SDHA and SDHB), complex III, complex 
IV and complex V. A significant increase in the amount of both SDHA and 
SDHB was observed in patients. 
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Fig. 36 
WB assessing the amount of the mitochondrial protein TOMM20 and Actin in MSA and control iPSC-derived neurons at 
35 DIV and graphs showing related quantification (values normalized for Actin). 
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Fig. 37 
WB assessing the amount of SDHA, complex V, complex III, SDHB, complex IV, 
complex I and Actin in MSA and control iPSC-derived neurons at 35 DIV and related 
graphs (values normalized for TOMM20). 
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The evaluation of mtDNA content, measured by qPCR through the 
simultaneous detection of the mitochondrial gene CytB and the nuclear gene 
APP, showed an increase in patients and in the affected twin. 
 
             
                    
 
 
 
 
 
 
 
 
 
 
 
 
The expression level of 5 genes involved in the synthesis of respiratory chain 
complexes (the mitochondrial-encoded MT-ND1 and MT-CO1 and the 
nuclear-encoded NDUFA2, NDUFA11, NDUFB4) was assessed through 
qPCR. A higher expression level was observed in patients respect to controls 
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Fig. 38 
Graphs showing mtDNA content in MSA and control iPSC-derived neurons measured by qPCR 
through the simultaneous detection of the mitochondrial gene CytB and the nuclear reference 
gene APP. 
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for all the genes, reaching statistical significance for NDUFA2. Twins 
displayed a more heterogeneous behaviour. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evaluate the possible presence of an unbalance between the translation 
of mitochondrial- and nuclear-encoded proteins, the amount of the complex 
IV subunits COXI (mitochondrial-encoded) and COXIV (nuclear-encoded) 
was assessed through WB. The COXI/COXIV ratio did not show significant 
differences between patients and controls and between the twins. 
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Fig. 39 
Graphs showing the expression level of the genes MT-ND1, MT-CO1, NDUFA2, NDUFA11 
and NDUFB4 in MSA and control neurons measured by qPCR. 
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The assessment of CoQ10 levels through HPLC did not reveal statistically 
significant differences between groups, although a trend of increase could 
be observed in patients’ group. 
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Fig. 40 
WB assessing the amount of the two subunits of respiratory chain complex IV COX I 
(mitochondrial-encoded) and COX IV (nuclear-encoded) in MSA and control iPSC-derived 
neurons and graphs showing quantification of COX I / COX IV ratio. 
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Fig. 41 
Graphs showing CoQ10 amount in MSA and control iPSC-derived neurons measured through HPLC. 
73 
 
The amount of 9 enzymes involved in CoQ10 synthesis (PDSS1, PDSS2, 
COQ2, COQ4, COQ5, COQ6, COQ7, ADCK3/COQ8A, COQ9) was 
assessed through WB. A generalized upregulation of these enzymes was 
observed in patients, reaching statistical significance for PDSS1, PDSS2, 
COQ4, ADCK3/COQ8A. The affected twin displayed the same trend of 
increase, although without reaching statistical significance. 
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Fig. 42 
WB assessing the amount of CoQ10 biosynthesis enzymes PDSS1, PDSS2, COQ2, COQ4, 
COQ5, COQ6, COQ7, ADCK3/COQ8A, COQ9 and Vinculin in MSA and control iPSC-
derived neurons. 
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Fig. 43 
Graphs showing quantification of WB assessing the amount of CoQ10 biosynthesis enzymes PDSS1, 
PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, ADCK3/COQ8A and COQ9 (values normalized for 
Vinculin). 
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Analyses on peripheral blood cells (PBCs) and brain tissue 
To further characterize mitochondrial functioning, analyses were performed 
also on PBCs and post-mortem brain tissue of patients affected with MSA 
and healthy controls. 
PBCs of 125 MSA patients (73 MSA-P and 52 MSA-C), 90 PD and 177 age-
matched healthy controls and post-mortem brain tissue of 58 MSA patients 
(21 MSA-P, 12 MSA-C and 25 undefined MSA), 25 PD and 99 age-matched 
healthy controls were analyzed. 
In all these samples mtDNA content was measured by qPCR through the 
simultaneous detection of a mitochondrial gene and a nuclear gene and 
analyzed through the ΔΔCt method. PBCs were analyzed through two 
independent combinations of mitochondrial and nuclear probes: CytB vs 
APP and ND4 vs RNaseP. Brain tissue was analyzed with a single probe 
combination (ND4 vs RNaseP). 
Analyses on PBCs showed a significantly increased mtDNA content in MSA 
respect to controls with both probe combinations, which was exclusively 
driven by MSA-C. Indeed, mtDNA content proved to be significantly 
increased in MSA-C respect to controls but not in MSA-P respect to controls. 
The analysis with the ND4/RNaseP probes combination also showed a 
significant increase of mtDNA in MSA-C respect to MSA-P. 
Analyses on post-mortem brain tissue confirmed most of the results 
observed in PBCs, showing a significant increase of mtDNA in MSA-C 
respect to controls, in MSA-C respect to all MSA samples and in MSA-C 
respect to MSA-P. 
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DISCUSSION 
The present study aimed to contribute to the comprehension of the still widely 
unknown pathogenic mechanisms of MSA and to lay the foundations for the 
development of new therapeutic approaches. 
The study has taken advantage from various techniques and has been based 
on different models: peripheral blood cells, fibroblasts and iPSC-derived 
neurons. Remarkably, this work represents the first comprehensive iPSC-
based model of MSA. 
As the pathogenic mechanisms of MSA are still elusive, many fields have 
been investigated, ranging from mitochondrial functioning to autophagy, 
alpha-synuclein accumulation and cell survival. 
 
Alpha-synuclein 
The role of alpha-synuclein in pathology is highly debated in the scientific 
community. Its heterogeous behavior raises many doubts about the causes 
which lead to its accumulation and aggregation and about the pernicious 
effect which is caused by the protein itself. Not only different subclasses of 
alpha-synucleinopathies are characterized by the involvement of different 
cellular subtypes (namely neurons or oligodendrocytes) or different brain 
areas, but many different protein conformations can be observed in disease. 
The evaluation of intracellular alpha-synuclein is particularly difficult because 
the exact description of the physiological and pathological conformations of 
the protein is still a matter of debate. On the one hand, some laboratories 
argue that alpha-synuclein native form is a folded tetramer of 58-60 kDa 
(Bartels et al., 2011; Wang et al., 2011). On the other hand, other 
investigators assert that the native form of alpha-synuclein is an unfolded 
monomer and that the higher molecular weight which can be observed in 
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native gel is due to an extended conformation of the protein (Fauvet et al., 
2012; Lashuel et al., 2013). Furthermore, the pathogenesis of alpha-
synucleinopathies has been associated with more complex forms of alpha-
synuclein, in particular oligomers and fibrils (Lashuel et al., 2013). However, 
investigating these specific mechanisms was beyond the aim of the present 
study, which was only focused on the monomeric form of the protein, which 
did not show significant differences between patients and controls at WB. 
More interesting results have been found evaluating the methylation pattern 
of SNCA CpG islands (CGIs). CGIs are short interspersed DNA sequences 
rich in CpG dinucleotides. Most CGIs are located at the sites of transcription 
initiation and are predominantly non-methylated. Silencing of CGI promoters 
can be achieved through epigenetic modifications, namely CpG methylation. 
(Deaton and Bird, 2011). Previous studies (Jowaed et al., 2010; Matsumoto 
et al., 2010) evaluated the SNCA sequence and identified two CpG-rich 
regions at the 5’ of the gene: the first including the promoter and the second 
located within intron 1 (-1074 to -26 from ATG) (Jowaed et al., 2010). The 
methylation of this latter region has been proven to be correlated with SNCA 
transcription regulation. Additional studies of the SNCA gene methylation 
pattern found that the CpG island within intron 1 was hypomethylated in 
brains of PD patients respect to healthy controls (Jowaed et al., 2010; 
Matsumoto et al., 2010). Furthermore, intron 1 is the same region which has 
been supposed to be involved in GATA-mediated SNCA regulatory 
mechanisms. In particular, in neuroblastoma cells, the silencing of the 
transcription factor GATA2 leads to a reduction of SNCA mRNA level and of 
alpha-synuclein amount (Scherzer et al., 2008). The finding that the CGI is 
less methylated in patients compared to controls and in the affected twin 
compared to the unaffected one opens new perspectives for the 
comprehension of MSA. Indeed, this epigenetic pattern may contribute to the 
onset of the disease by promoting the expression of the gene and, 
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subsequently, the synthesis of the protein. This finding is only partially 
consistent with qPCR data, which show an increased level of SNCA 
expression in patients only at 70 DIV. However, it is tempting to speculate 
that alternative regulatory mechanisms act in the early phase of 
differentiation to counterbalance the effect of hypomethylation, restoring the 
equilibrium between patients and controls. The assessment of GATA2 
expression levels seems to confirm this hypothesis, showing a reduced 
GATA2 expression in patients at 35 DIV, which may be sufficient to normalize 
the otherwise altered levels of SNCA transcript. However, further 
investigation is needed to confirm this hypothesis. In particular, it will be 
important to explore the involvement of all the pre- and post-transcriptional 
regulatory mechanisms which have been described so far for SNCA gene 
(transcription factors (Scherzer et al., 2008; Clough et al., 2009; Dermentzaki 
et al., 2016), lncRNAs (Mizuta et al., 2013) and miRNAs (Junn et al., 2009; 
Doxakis 2010)) and to evaluate the presence of alpha-synuclein oligomers 
and fibrils through proper techniques (e.g. thioflavin staining). 
As alpha-synuclein pathology in MSA mainly affects oligodendrocytes, this 
study would strongly benefit from the generation of iPSC-derived 
oligodendroglia and from the establishment of neurons-oligodendrocytes co-
coltures. This achievement would allow to investigate alpha-synuclein 
expression in glial cells and to assess protein cell-to-cell transfer.   
However, the available differentiation protocols (Douvaras and Fossati, 
2015) for oligodendroglia are still characterized by low efficiency and have to 
be improved before being used in an extensive project which requires a high 
amount of mature and well differentiated cells.   
 
Apoptosis and cellular survival 
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To investigate whether patients’ fibroblasts and iPSC-derived neurons 
displayed a different survival rate or signs of cellular suffering, many 
experiments have been carried out. The assessment of the apoptosis-related 
markers Bax (pro-apoptotic), Bcl2 (anti-apoptotic) and cleaved Caspase 3 
(pro-apoptotic) did not provide significant results. Differently, the assessment 
of the amount of various neuronal markers in iPSC-derived neurons at two 
different time-points showed a clear pattern of neuronal suffering which 
proved to be related to the progression of differentiation. In particular the 
finding of a remarkable reduction of the catecholaminergic marker TH, the 
axonal marker tau and the synaptic marker synapsin I in patients’ neurons at 
70 DIV is indicative of neurites’ damage and of a reduced dopaminergic 
neurons’ survival rate. This is further confirmed by the observation that only 
synapsin I, specifically located at synapses, is reduced, whereas synapsin 
III, which has been identified also in other cellular compartments, has not 
shown significant differences between patients and controls. (Porton et al., 
2011) The finding of the same behavior in twins further supports the 
hypothesis. Furthermore, it is important to notice that these signs of cellular 
suffering can be observed only at 70 DIV and not at 35 DIV, demonstrating 
that neuronal damage is correlated with the progression of differentiation 
and, more in general, with aging. 
 
Autophagy 
Autophagy has been widely studied in alpha-synucleinopathies and an 
impairment in this pathway has been described. (Xilouri et al., 2016) 
An autophagic defect has been detected in PD, both in autoptic samples and 
in animal models. (Klucken et al., 2012; Yu et al., 2009, Crews et al., 2010) 
Remarkably, the most important risk factor for the development of PD and 
DLB is represented by mutations in GBA, the gene encoding the lysosomal 
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enzyme glucocerebrosidase. Furthermore, glucocerebrosidase dysfunction 
and alpha-synuclein accumulation seem to be strictly correlated, enhancing 
each other in a self-propagating fashion. (Aflaki et al., 2017; Mazzulli et al., 
2011) 
An activation of the autophagic pathway has been observed also in MSA 
brain samples. (Schwarz et al. 2012; Tanji et al., 2012) 
The present study has assessed autophagy from many points of view and 
has demonstrated a strong impairment in MSA. 
Data on fibroblasts have not provided major hints, probably because these 
cells are not affected in the disease.  
Differently, iPSC-derived neurons, evaluated only at 35 DIV, have shown a 
strong activation of autophagy accompanied by an impairment of the same 
pathway. This observation is particularly supported by the findings observed 
with LC3 II, both at basal level and after the administration of bafilomycin A1, 
a V-ATPase inhibitor which causes the block of the fusion between the 
autophagosome and the lysosome (Klionsky et al., 2012). 
LC3 is commonly used to monitor the autophagic pathway. Two forms of LC3 
can be detected: LC3-I and LC3-II. LC3-I is the cytosolic form of the protein 
and can be converted to LC3-II through conjugation with 
phosphatidylethanolamine. LC3-II is associated with autophagosomes and 
is degraded after fusion with lysosomes. The basal level of LC3-II can be 
considered as a good marker of autophagic activity, whereas the change in 
protein amount after treatment with autophagy inhibitors is a reliable marker 
of the effectiveness of the autophagic flux. 
In this study LC3-II basal level was found to be increased and autophagic 
flux (measured as LC3-II treated/untreated) was found to be reduced both in 
patients and in the affected twin. 
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Other investigations further supported the impairment of autophagy in 
patients. In particular, the activity level of some lysosomal enzymes, namely 
α- and β-Mannosidase, proved to be significantly reduced in MSA.  
Furthermore, lipid analyses, although only preliminar and performed on a 
limited number of subjects, provided some interesting hints consistent with 
the hypothesis of an autophagic dysfunction which also affects lipidic 
turnover. In particular, the finding of an increased level of GlucosylCeramide 
and LactosylCeramide and of a reduced level of Ceramide in patients is 
intriguing, although further analyses are required to confirm the hypothesis 
and to understand why the finding is not accompanied by a reduction of GBA 
activity. 
 
Mitochondrial dysfunction 
Mitochondrial dysfunction has proved to play an essential role in alpha-
synucleinopathies. 
The present study further supports this hypothesis, suggesting a strong 
alteration of several mitochondrial mechanisms. 
In particular, two main findings have emerged from the study: a mitochondrial 
dysfunction and an up-regulation of mitochondria-related pathways. 
Mitochondrial dysfunction is confirmed by the results of spectrophotometric 
analyses, which show a reduction of respiratory chain activity in patients, 
both in fibroblasts and in neurons. Patients’ fibroblasts also display a trend 
of reduction of maximal respiration rate, although the high variability among 
cell lines does not allow to reach statistical significance. 
Differently, the mitochondrial up-regulation, detectable mainly in neurons, is 
suggested by many findings. Total mitochondrial mass (assessed through 
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WB and qPCR) is increased, as well as the amount of SDHA and SDHB, the 
expression levels of various genes involved in the synthesis of respiratory 
chain complexes’ subunits and the amount of several enzymes involved in 
CoQ10 biosynthesis.  
These two findings may be closely related to each other, being the up-
regulation of mitochondrial pathways a possible compensatory mechanism 
to an underlying mitochondrial dysfunction.  
An intriguing comprehensive hypothesis is that mitochondrial dysfunction 
may be closely related to the autophagic impairment. A dysregulation in 
autophagy, which impairs also the mitophagic machinery, would lead to a 
defect in mitochondrial degradation and to the accumulation of damaged 
senescent organelles, which do not work properly and further trigger 
mitochondrial biogenesis in a self-propagating fashion. 
The results related to mtDNA are particularly interesting, showing a 
significant increase of mtDNA content in MSA-C both in peripheral blood cells 
and in brain tissue. The reliability of the finding is supported by the high 
number of patients and controls involved in the analyses and by the 
replication of the analyses with two different experimental methods (i.e. with 
two different combinations of mitochondrial and nuclear probes). Data 
obtained on fibroblasts and neurons are not so striking, but they have been 
performed on a far smaller cohort of subjects. 
The finding of a selective alteration of mtDNA content in the cerebellar 
subtype of MSA is particularly noticeable because MSA-P and MSA-C are 
usually considered as different manifestations of the same disease and the 
reported finding may shed light on the different pathogenic mechanisms at 
the basis of these two forms. In this view, it is important to observe that 
mitochondrial dysfunction is a common finding of cerebellar diseases, both 
as a causative mechanism and as a secondary clinical manifestation. The 
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close relationship between mitochondrial dysfunction and cerebellar 
diseases is indicative of the fact that the result observed in MSA may be the 
consequence of the early and massive cerebellar involvement which can be 
observed in this subtype of the disease. The recent description of a selective 
depletion of CoQ10 in the cerebella of MSA patients (Schottlaender et al., 
2016; Barca et al., 2016) further supports this hypothesis, providing evidence 
for the strict relationship between cerebellar degeneration and mitochondrial 
dysfunction. 
The finding of mtDNA alteration in MSA-C does not only provide an 
interesting hint to further understand the pathogenic mechanisms at the basis 
of the disease but may also be useful in clinical practice. Indeed, mtDNA 
content in peripheral blood cells may be a useful tool for the differential 
diagnosis of alpha-synucleinopathies, although further investigation is 
needed to confirm this finding and to assess sensitivity and specificity of the 
test.    
mtDNA content has been assessed also in a cohort of PD patients (both 
PBCs and brain tissue), without significant results (respect to controls). 
However, mtDNA content in PD patients has already been investigated in 
previous studies, although with conflicting observations. In particular, one 
study (Pyle et al., 2016) has detected a reduction of mtDNA in PD PBCs and 
brain samples, while another one (Wei et al., 2017) has not found significant 
differences in brain samples. 
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CONCLUSIONS 
The present study aimed to investigate the pathogenic mechanisms of MSA, 
a disease whose etiology is still widely unknown but which causes a 
remarkable burden for patients and still lacks an effective treatment. 
The study provides a comprehensive description of various experimental 
models of MSA involving fibroblasts, iPSC-derived dopaminergic neurons, 
peripheral blood cells and brain tissue. 
As an univocal hypothesis about MSA pathogenesis is absent, various 
potentially causative molecular mechanisms have been taken into 
consideration, ranging from alpha-synuclein expression to autophagy and 
mitochondrial functioning.  
The opportunity to rely on various models has further strengthened the 
robustness of the observations. 
The development of the iPSC-based neuronal model is remarkable because 
this technique has almost never been used in this disease so far. 
The results of the study outline an impairment of specific pathways: alpha-
synuclein gene expression regulation, autophagy and mitochondrial 
functioning. 
All these pathways may be related to one another and it is intriguing to 
hypothesize that a single link connects all of them. A comprehensive 
hypothesis could be that autophagic impairment also affects mitophagy, 
leading to the formation of senescent damaged mitochondria which, in turn, 
up-regulate the pathways involved in their own maintenance (e.g. CoQ10 
biosynthesis). Malfunctioning mitochondria may then contribute to cellular 
suffering and, eventually, death. The role of alpha-synuclein dysregulation in 
this context may be found in the already described link between alpha-
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synuclein aggregation and lysosomal impairment, deeply investigated in 
Parkinson’s disease. However, further investigation is needed to clearly 
understand the whole pathogenic network. 
In the future, it will be important to unravel the role of alpha-synuclein in more 
detail, assessing the presence of oligomeric and fibrillar forms of the protein, 
evaluating the presence of protein and/or mRNA in the extracellular 
environment or in exosomes and assessing the possible transfer of the 
protein to oligodendroglia establishing co-coltures of iPSC-derived neurons 
and oligodendrocytes. 
It will be important to further investigate the impairment of autophagy, 
extending lipid analyses to a proper number of patients and controls and 
assessing the precise connection between autophagic dysfunction and 
alpha-synuclein accumulation. 
It will be crucial to perform other experiments for the dissection of the 
mitophagic machinery, which could represent a potential connection 
between autophagic and mitochondrial defects.  
Finally, it is important to remark that the establishment of a human neuronal 
model of the disease may be of great usefulness for the assessment of the 
therapeutic effect of novel pharmacological compounds and for regenerative 
medicine techniques. 
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